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ABSTRACT 
 
Hepatitis C virus (HCV) currently affects ~5% of the world’s population and has 
relatively limited treatment options for infected patients. Genetic suppressor elements 
(GSE) derived from a gene or genome of interest can act as transdominant inhibitors of a 
particular biology function presumably by binding to and blocking an essential 
interaction surface for protein activity. Taking advantage of hepatoma cell line n4mBid, 
that supports all stages of the HCV life cycle and strongly report HCV infection by a 
cell-death phenotype, we developed an iterative selection/enrichment strategy for the 
identification of GSE against HCV.  Using this strategy, a library expressing random 
fragments of the HCV genome was screened for sequences able to suppress HCV 
infection. A 244 amino acid gene fragment, B1, was strongly enriched after 5 rounds of 
selection. B1 has a very high net positive charge of 43 at neutral pH and a high charge-
to-mass (kDa) ratio of 1.5. We show that B1 expression specifically inhibits HCV 
replication, apparently due to its high positive charge. We also show that recombinant 
positively charged proteins can inhibit HCV infection, when supplied in vitro.  
In addition, eGFP-fused B1 potently penetrates both adherent and suspension cells with 
>80% of cells taking up the protein. Importantly, we show that B1 not only facilitates 
cellular uptake, but allows protein cargo to reach sites of biological relevance. B1 also 
delivers non-covalently conjugated RNA and DNA across the cell membrane to 
cytosolic and nuclear sites, with efficiency comparable to commercially available 
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cationic lipid reagents. Our data suggest that B1 utilizes cell-surface glycans and 
multiple competing endocytic pathways to enter and traffic through cells. 
During a separate screening carried out in our lab, we identified a TACR3 inhibitor SB 
222200 that had significant HCV activity. We go on to show that both TACR1 and 
TACR3 receptors are expressed in the HCV-permissive Huh 7.5 cell line. We also show 
that both TACR1 and TACR3 inhibitors significantly inhibit HCV infection. These 
results point to the potential for TACR1 antagonists in treating patients infected with 
both HCV and HIV.  
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1. INTRODUCTION  
 
 
Hepatitis C virus (HCV) is a single-stranded, enveloped, positive-sense RNA virus of 
the Flaviviridae family (1). HCV infection affects over 180 million people worldwide 
(2) and is the leading cause of liver transplantation developed countries (3). Until 
recently the only currently approved HCV therapy involved a 24-48 week regimen of 
combination therapy involving pegylated interferon alpha and ribavirin (4). Interferon 
alpha-ribavirin treatment is costly, time-consuming and riddled with serious and 
debilitating side effects such as depression, fatigue and flu-like symptoms (5, 6), 
resulting in many patients being unable to complete the therapy. In addition, only 50% 
of treated patients infected with the most common genotype achieved sustained 
virological response (SVR) after receiving interferon-alpha-ribavirin therapy(7). The 
current standard of care for HCV infection involves a combination of two HCV protease 
inhibitors, boceprevir and telaprevir, along with interferon alpha-ribavirin (8). Though 
this treatment can achieve SVR rates approaching 80%, it is accompanied with more 
serious side effects and poses significant risks to patients with advanced liver disease 
(9). In addition, both boceprevir and telaprevir are prone to resistance development and 
they share resistant mutations (10). Thus, there remains an urgent need to develop new 
treatments to HCV outside the current paradigm of protease inhibition. 
This research aimed to identify new genetic elements that inhibit HCV infection, and to 
characterize a new class of drugs that inhibit HCV infection. We first developed a 
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genetic screening approach that links HCV inhibition to cell survival. Using this 
approach, we identified a highly positively charged protein able to inhibit HCV 
replication. In addition, this protein was also found to have excellent cell penetration 
ability. These studies expands the repertoire of current anti-HCV molecules and 
hopefully will lead to safer, less demanding and more cost-effective treatment options 
for HCV-infected patients in the future. 
 
1.1 Hepatitis C virus 
1.1.1 HCV virology 
HCV is a single-stranded, enveloped, positive-sense RNA virus of the Flaviviridae 
family (1). HCV exhibits an estimated mutation rate of 2.5 x 10-5 mutations per 
nucleotide per genome replication and exists as a quasispecies in each patient (11, 12). 
Six major genotypes and numerous subtypes of HCV have been identified around the 
world (13). HCV-induced liver cirrhosis and cancer is the leading cause for liver 
transplantation in developed countries (3). 
 
The HCV RNA genome consists of approximately 9600 nucleotides, and is translated 
intracellularly into several structural and non-structural proteins. The structural proteins: 
capsid protein core and envelope proteins E1 and E2, form the virion that encloses the 
viral RNA. The non-structural proteins:  p7, NS2, protease and helicase NS3 (14, 15), 
NS4A, NS4B, NS5A, and RNA dependent RNA polymerase NS5B (16), form the viral 
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replication complex and aid in the assembly of new virions. The HCV life cycle can be 
described in terms of three major steps: entry, replication, and virus assembly/release: 
 
Entry. HCV requires a number of cell surface receptors to enter cells including SR-BI 
(17), CD81 (18), and the tight junction proteins claudin-1 (19), occludin (20) and the 
Neimann-Pick C1-like 1 (NPC1L1) cholesterol absorption receptor(21). After 
attachment, the HCV virion is internalized by the host cell via clathrin-mediated 
endocytosis. The acidic environment in the late endosome triggers fusion mediated by 
HCV E1 and E2 envelope proteins(22) between the viral and cellular membranes (23), 
causing the release of viral RNA into the cytoplasm. 
 
Replication. With the viral RNA inside the cell, translation takes place at the rough 
endoplasmic reticulum (ER) (24). Unlike typical mRNAs, translation of HCV RNA is 
initiated at its internal ribosomal entry site (IRES) contained within the 5’ untranslated 
region (UTR) of the viral RNA(25). All viral proteins are expressed in a single open 
reading frame, and are initially translated as a long polyprotein 3011 amino acids in 
length(26). The viral polyprotein is then processed into mature viral structural and non-
structural proteins by cellular and viral proteases (27). HCV genome replication is 
believed to take place in a membranous web structure in the ER induced by HCV NS4B  
(28). In the membranous web, the HCV genome replication is carried out within the 
replication complex by the viral RNA-dependent RNA polymerase NS5B(16, 29). 
However, NS5B lacks a proof-reading mechanism, making viral RNA synthesis highly 
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error-prone(30). This leads to significant variations of the viral genome within a single 
patient, called a quasispecies (30). As is the case with human immunodeficiency virus 
(HIV) (31), the viral quasispecies facilitates the emergence of drug-resistant viral 
variants, making it difficult to eradicate HCV infection in vivo with any single drug 
therapy. 
 
Virus assembly/release.  Due to the presence of HCV core on the cytosolic side of the 
ER membrane, HCV assembly is thought to initiate in the cytosol. Nascent particles are 
transferred into the ER lumen to access cellular secretory pathways for release into the 
extracellular environment (32).  
 
1.1.2 Systems available for the study of HCV 
Even though HCV was first identified more than two decades ago (33), HCV antiviral 
development was hampered for many years by the lack of a suitable cell culture 
system(34). In vitro-transcribed HCV RNA of most genotypes proved infectious in 
animal models, but could not establish infection in cell culture(35). In 1999, a 
breakthrough was made with the discovery of the HCV replicon system, which is able to 
replicate efficiently in hepatocellular carcinoma cells (36). HCV replicon is a truncated 
form of the HCV genome encoding the HCV non-structural proteins NS3-NS5B. The 
replicon system facilitated the study of the replication aspects of the HCV life cycle, but 
did not support the production of infectious HCV particles. Another milestone in the 
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study of HCV was the development of infectious HCV pseudoparticles (HCVpp) in 
2003. 
  
HCVpp are lentiviral particles bearing HCV envelope glycoproteins E1 and E2. HCVpp 
recapitulate most of the steps of HCV entry, including cell surface receptor attachment, 
endocytosis and virus-host membrane fusion (37). However, HCVpp contain 94% more 
cholesterol than the authentic HCV and have reduced sensitivity toward cholesterol-
modifying HCV inhibitors (21).  Despite the availability of the HCV replicon and 
HCVpp systems to study HCV replication and entry, respectively, a convenient model 
system to study the entire life cycle of HCV was not available until a cell culture-
produced strain of HCV (HCVcc) was discovered in 2005  (38) .  
 
HCVcc was derived from JFH1, a genotype 2a isolate of HCV that was first found to be 
able to replicate efficiently in vitro, and then found to produce infectious virus particles 
in cell culture (39, 40). The HCVcc model enabled for the first time the study of all the 
steps of the HCV life cycle in a convenient cell culture format. Since then, a number of 
JFH-1 based intergenotypic recombinant viruses containing the core-NS2 sequence of 
prototype strains of HCV genotypes 1a, 2a, 3a, and 4a have been created, expanding the 
repertoire of infectious HCVcc genotypes (41, 42). Of these Jc1, the chimeric J6/JFH 
HCV genotype 2a isolate, and the JFH HCV genotype 2a isolate, are used in our lab. Jc1 
was developed in a bid to obtain more infectious HCVcc recombinants. This isolate 
combines the Core, E1, E2 and p7 proteins of the patient-derived J6 isolate(43), with the 
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NS3-5B proteins of the patient-derived JFH-1 isolate(40, 41). When these two isolates 
were fused at the junction between the first and second transmembrane domains of the 
NS2 protein the resulting chimeric virus, termed Jc1, showed improved infectivity 
compared with the JFH isolate(41).  
 
The final system developed involves a combination of the HCV replicon system, and 
HCV structural proteins. In this system, HCV virions are generated using J6 Core, E1 
and E2 structural proteins, and then transcomplemented with JFH HCV replicon RNA 
resulting in transcomplemented HCV (HCVtcp)(44). HCVtcp can enter cells as HCVcc 
would, and then RNA replication can proceed via the JFH HCV replicon. However, due 
to the absence of HCV structural proteins in the JFH HCV replicon, no HCV virions can 
be produced in HCVtcp infected cells. Thus, the HCVtcp system allows for investigation 
of HCV entry and replication, in the absence of assembly/release. Since the virion used 
is a complete HCV virion, it is a potentially more accurate model of HCV entry than the 
HCVpp system. However, unlike HCVpp, HCVtcp virions are currently limited to using 
J6 HCV structural proteins(44). 
 
1.1.3 Pharmacological advances in HCV inhibitor development 
Since the development of the HCV replicon and HCVcc systems, there has been a great 
increase in the number of potential pharmacological treatments for HCV being identified 
and being pushed into clinical trials. These inhibitors may be organized into a number of 
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classes, based on the mechanism by which HCV infection is inhibited. All treatments 
may be classified as either direct acting or indirect acting antivirals.  
 
1.1.3.1 Indirect acting antivirals 
Indirect acting antivirals are compounds that do not specifically target viral protein or 
genetic material, and instead mediate antiviral activity by interacting specifically with 
the host. Indirect acting antivirals have a weaker tendency to foster drug-resistant 
mutants, but bear an increased risk of side effects. Interferon alpha, used in the standard 
of care for treating HCV, is an example of a non-direct acting antiviral since it 
functionally stimulates the host antiviral response by activating the JAK-STAT pathway 
(45).  
 
1.1.3.2 Indirect acting antivirals: Cyclophillin inhibitors 
Small molecule inhibitors of cyclophillins have been demonstrated to show significant 
inhibition of HCV infection in vitro. This has lead to significant interest in developing 
cyclophillin inhibitors as potential pharmacological treatments for HCV. Cyclophillin B 
has been demonstrated to bind to the HCV polymerase NS5B and enhance its RNA 
binding activity (46). Cyclophillin inhibitors can bind to cyclophillin B, preventing its 
interaction with the HCV polymerase and thereby inhibiting viral replication. As such, a 
number of cyclophillin inhibitors have entered into clinical trials. A promising 
cyclophillin inhibitor currently in clinical trials is NIM811. Despite previously having 
demonstrated excellent anti-HCV activity when used in vitro, NIM811 had no effect on 
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viral loads when used as a monotherapy. In addition, when used in combination with 
interferon, the drug failed to show a significant increase in sustained virological response 
(SVR) compared with control groups (47).  
 
1.1.3.3 Indirect acting antivirals: HCV vaccines 
Despite the development of an efficient in vitro model for studying HCV infection, the 
lack of a suitable animal model has greatly slowed the development of potential HCV 
vaccines. However, one such vaccine TG4040 has recently shown efficacy in a phase I 
clinical trial(48). TG4040 is a replication-deficient poxvirus that expresses HCV NS3, 
NS4 and NS5B proteins in patients. The expression of these proteins potentially leads to 
the induction of the host’s natural immune response which constitutes its antiviral 
activity. TG4040 has been previously demonstrated to induce long lasting immune 
responses after initial vaccinations in animal models (49). Consistently, the phase I trial 
showed a sustained anti-HCV immune response in vaccinated patients. In addition, 
patients showed significantly reduced viral loads (53% reduction in viral RNA levels) 
and vaccine administration was relatively free of adverse effects apart from mild to 
moderate injection site reactions(48). Overall, TG4040 shows promise as a future anti-
HCV vaccine. 
 
1.1.3.4 Direct acting antivirals 
Direct acting antivirals are compounds that specifically interact with a viral protein or 
nucleic acid. Drugs in this class are typically designed to be very specific to their target, 
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and tend to present a lower risk of side effects due to unintentional interactions. These 
drugs may be further grouped based on their specific target: protease inhibitors; 
nucleoside and non-nucleoside polymerase inhibitors; NS5A inhibitors; and monoclonal 
antibodies. However, this target specificity means an increased incidence of viral 
resistance, especially when treating viruses with high mutation rates like HCV (11). We 
will next discuss the development of the leading protease inhibitors.  
 
1.1.3.5 Direct acting antivirals: protease inhibitors 
Protease inhibitors are direct acting antivirals that selectively inhibit the protease activity 
of their target virus. Protease inhibitors developed for treatment of human 
immunodeficiency virus (HIV), such as darunavir and ritonavir, were found to be quite 
effective (50). The success of these and earlier anti-HIV protease inhibitors fueled 
interest in developing protease inhibitors against HCV. However, early development 
efforts were slowed both by the relatively shallow substrate binding site of the HCV 
protease (51), and the delay in developing an HCV infection model (HCVcc). Despite 
these initial limitations, Boehringer-Ingleheim developed a protease inhibitor (BILN 
2061) that appeared to be very efficacious (52). However, this compound also exhibited 
high cardio toxicity which eventually lead to its failure as a potential treatment option 
(52). The proof of concept demonstrated with BILN fueled the development of candidate 
protease inhibitors by many pharmaceutical companies. Recently two of these drugs, 
boceprevir and telaprevir, became the first FDA-approved small molecule inhibitors of 
HCV.  
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1.1.3.6 Direct acting antivirals: Telaprevir 
Telaprevir (marketed as Incivek) is a protease inhibitor initially developed and 
characterized by Vertex Pharmaceuticals. Telaprevir was designed as a peptidomimetic 
of the HCV protease cleavage site, and was demonstrated to be a selective, reversible 
inhibitor of the HCV protease(51). It was also found to be quite efficacious both in vitro 
and in a mouse model (51). In this study, telaprevir was demonstrated to have an oral 
bioavailability of at least 25%, and in particular was found to be present in the liver at 
concentrations at least 35 times that of the plasma(51). Telaprevir was also found to have 
a longer half-life when administered orally (~3 hours) compared to intravenous 
administration (~1.5 hours)(51).  
 
Due to the relatively high chance of resistance mutants emerging during telaprevir 
treatment, the efficacy of telaprevir was tested in combination with interferon alpha 
therapy (53). A randomized, double blind, placebo controlled trial carried out in Europe 
achieved SVR in a significantly increased number of patients when telaprevir was 
administered in combination with interferon alpha (65% SVR) than the interferon alone 
group (48%) (53). In addition the effect of the presence of ribavirin on this expected 
synergy was also tested. This trial demonstrated the efficacy of the drug, and was 
particularly significant in that the overall treatment time could potentially be reduced 
from 48 weeks to 2 weeks (53). Reducing the treatment time of interferon therapy is 
important due to both the reduction in the cost to the patient, and the reduced duration of 
interferon’s side effects which affects patient compliance. A significant result of this trial 
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was the relatively mild nature of the drug’s adverse effects, which include pruritus and 
rash. These symptoms occurred significantly more frequently in patients receiving 
telaprevir/interferon (69%) compared with patients receiving interferon only (35%). The 
rashes found in the telaprevir group were found to be similar to those observed with drug 
reactions. Grade 3 rash was found in 7% of patients receiving telaprevir, but no grade 4 
rash was reported(53).  Overall 12% of patients receiving telaprevir discontinued 
treatment, compared with 7% of patients receiving interferon only. In a simultaneously 
conducted trial in the United States, similar efficacy was reported(54). A significant 
result of this trial was the reported efficacy of telaprevir when treating black patients. 
Black patients are typically less responsive to interferon therapy compared with other 
groups of patients due to the increased prevalence of the TT allele of the IL28b single 
nucleotide polymorphism, which was found to determine patient interferon response 
(55). The SVR obtained with black patients receiving telaprevir was significantly greater 
(44%) than those receiving interferon only (11%) (54). The efficacy of the treatment, 
reduction in treatment time, and relatively manageable side effects reported with 
telaprevir use eventually lead the drug to be approved for treatment of HCV by the Food 
and Drug Administration (FDA) in May of 2012.  
 
1.1.3.7 Direct acting antivirals: Boceprevir 
Boceprevir (marketed as Victrelis) is a protease initially developed by Schlering-Plough. 
Boceprevir contains a ketoamide moiety as the backbone and was designed to bind the 
active site of the HCV protease (56). Boceprevir was designed to be selective for the 
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HCV protease with irreversible binding (56), but later studies confirmed that its 
inhibition was indeed reversible (57). Boceprevir was also demonstrated to be extremely 
efficient at inhibiting both HCV replicon replication and HCV protease activity in vitro, 
with no reported cytotoxicity(56). Initial clinical trials tested the efficacy of boceprevir 
monotherapy as well its ability to induce drug resistant HCV mutants. In one such trial 
involving patients unresponsive to interferon-ribavirin therapy, SVR was not achieved in 
a significant percentage of patients tested (58). In addition, a number of drug resistant 
strains of HCV emerged which showed resistance to both boceprevir and telaprevir(58). 
The result of this and other studies lead to the development of boceprevir as a 
combination therapy with interferon alpha instead of as a monotherapeutic. Bocaprevir 
was then tested in an open label, randomized trial in North America and Europe to 
determine its efficacy as combination therapy with interferon alpha/ribavirin. In this 
study, patient groups received either the standard interferon/ribavirin therapy, or various 
combinations of interferon/bocaprevir therapy for at least 28 weeks and up to 48 
weeks(59). The results indicated significantly higher SVR rates in all groups where 
bocaprevir was included as part of the therapeutic regimen, but it was noted that lower 
doses of ribavirin was associated with a higher rate of viral breakthrough (59). Similar to 
the results obtained in the trials of telaprevir, rapid clearance of viral loads was 
associated with SVR, which lead to the conclusion that treatment times in subsequent 
trial could be potentially be reduced. In addition, black patients receiving bocaprevir also 
showed a significantly increased SVR rate (53%) compared with those receiving 
interferon only (13%). Reported adverse effects included fatigue, anemia, nausea and 
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headache which are the side effects interferon/ribavirin treatment. Incidence of the 
reported side effect did not vary significantly between bocaprevir treatment and the 
control group. Given the success of this initial trial, subsequent phase 3 trials were 
carried out. The first of these trials tested the effect of bocaprevir/interferon combination 
therapy, while varying the bocaprevir treatment duration after a lead-in with 
interferon/ribavirin(60). The second tested the ability of boceprevir to induce a SVR in 
patients who did not respond to previous interferon/ribavirin treatment (61). In both 
these trials the SVR in boceprevir treated groups was significantly higher than that the 
control groups, and adverse effects were no more significant than appearing in control 
groups. As with telaprevir, the clinical efficacy and tolerability of boceprevir lead to its 
approval for treatment of HCV by the FDA in April of 2012. 
 
1.2 Tachykinins 
Tachykinins (also known as neurokinins) are peptides characterized by a common C-
terminal sequence that binds to and activates a cell surface-localized tachykinin receptor 
(62). The three main tachykinin peptides (Substance P (SP), Neurokinin A (NKA) and 
Neurokinin B (NKB)) are distributed throughout the body, but are usually predominantly 
found in the central nervous system (CNS) (63, 64). The tachykinin receptor is a G-
protein coupled receptor containing seven trans-membrane helices(65). Three different 
tachykinin receptors (TACR) have been identified – tachykinin receptors 1, 2 and 3 
(TACR1, TACR2 and TACR3) – and each receptor can be activated by any of the three 
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main tachykinin peptides (66). This apparent lack of specificity is likely due to a high 
homology at the ligand-binding site among these receptors(67).  
 
Typically the binding of an agonist to the receptor initiates a cascade of intracellular 
signaling events. Guanosine diphosphate (GDP) is first phosphorylated to guanosine 
triphosphate (GTP), activating the intracellular enzyme phospholipase C (PLC)(68). 
PLC can then, in turn hydrolyze phosphatidyl inositol bisphosphate (PIP2) forming 
inositol triphosphate (IP3) and diaglycerol (DAG)(68). These two molecules then act to 
increase the calcium concentration in the cytoplasm from two different sources. IP3 can 
bind to and activate the IP3 receptor on the ER membrane(69). This results in the release 
of calcium from the ER to the cytoplasm. DAG can activate protein kinase C (PKC) 
which opens L-type calcium channels in the cell membrane, enabling calcium influx 
from the extracellular environment(70). Perhaps due to this non-specific signal cascade, 
tachykinins can be responsible for a wide range of effects. This, combined with the 
relatively large tissue distribution, leads to tachykinins being involved in a number of 
functions including: neuronal survival and regeneration; gastric mobility; regulation of 
respiratory mechanisms; and the expression of pro-inflammatory cytokines (71-73).  
 
Due to the large number of physiological functions mediated by tachykinin receptors, 
TACR antagonists, have been tested for a wide range of indications in clinical trials. 
TACR1 antagonist aprepitant has been tested as an antiemetic, an antidepressant, a 
CYP34A inhibitor, and to treat urge urinary incontinence (74-77). TACR1 antagonist CP 
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99994 has been tested as a post-operative analgesic (78). TACR2 antagonists nepadutant 
and saredutant have been tested for the treatment of irritable bowel syndrome, and the 
inhibition of NKA induced bronchoconstriction (79, 80). Finally, TACR3 antagonist 
osanetant has been tested as an anti-psychotic (81). 
 
In addition to their roles in native body functions, tachykinin ligands and receptors have 
been implicated in the infection of some viruses (82, 83). For HIV it was observed that 
HIV-infected individuals had significantly increased levels of SP (84). It was also shown 
that SP binding lead to increased HIV replication in infected cells, including the 
activation of latently infected immune cells (85, 86). It was then shown that TACR1 
antagonists inhibit HIV infection in vitro (83, 87, 88). Aprepitant, a TACR1 antagonist, 
was used in a clinical study for HIV treatment, but the study failed due to the inability to 
reach effective physiological concentrations at safe doses (89). The first, and only thus 
far implied role of tachykinins and HCV occurred when a TACR3 tachykinin receptor 
antagonist, SB 222200, appeared as a hit in a screen for anti-HCV small molecules 
carried out in our lab (90).  
 
1.3 Genetic suppressor elements 
Genetic suppressor elements (GSEs) are fragments of a genome that act to inhibit a 
function of the original gene from which they were derived (91). A GSE can exert its 
inhibitory function through a variety of mechanisms. For example, a GSE can encode a 
peptide that competes for a binding site or a substrate with the protein from which it was 
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derived, thereby suppressing the activity of the protein. GSEs have been identified 
against a number of different viruses, including rabies virus (92), HIV (93) and bovine 
viral diarrhea virus (94).  
 
In addition to their role as tools for studying viruses, GSEs are potential therapeutic 
agents. GSEs have been found that decrease viral loads of bovine viral diarrhea virus 
(BVDV) by 100- to 1000-fold [20], a potency on par with some of the best BVDV 
antiviral candidates in preclinical and clinical trials [27]. Even if the GSEs themselves 
are not ideal drugs, suppressor elements can serve as templates for the creation of small 
molecule or peptide mimetics, which can in turn be used as potent antivirals. Such a 
peptide, called enfuvirtide, based on the fusiogenic domain of the HIV envelope protein, 
has been developed as an anti-HIV therapy (95). This treatment, marketed under the 
name Fuzeon, is used to great effect in treating patients who have become resistant to 
more traditional drugs used in Highly Active Anti-Retroviral Therapy (HAART)(96). No 
anti-HCV GSEs have yet been reported, partly due to the lack of a convenient cell 
culture system supporting HCV infection in vitro for many years.  
 
GSE identification typically involves selection for a desired phenotype from a 
fragmented library derived from a target genome and the recovery of potential GSEs 
from the selected cells. The fragmented library is usually obtained by limited digestion 
of the target genome with DNaseI and purification of DNA fragments of a given size 
range.  The potential library size depends on the size of the target genome. The HCV 
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genome has 9600 nucleotides and potentially contains 9600 distinct equal sized 
fragments. Depending on the size range of the purified fragments, the potential library 
size can be 10-100-fold larger than the target genome size. Due to the large 
complexity/size of genetic libraries generated from fragmented genomes, an effective 
phenotypic selection system is essential to separate true GSEs from genomic fragments 
that do not mediate the desired effect. The most convenient and commonly used 
selection pressure for viral systems is viral cytotoxicity. In such systems, virus-
suppressing GSEs confer an easily selectable growth advantage phenotype to host 
cells(91).  
 
HCV does not usually kill its target cells as a part of its infection cycle and is thus 
considered to be a non-cytopathic virus. To create of a selection system that allows anti-
HCV molecules to confer a growth advantage to host cells,  our lab engineered a 
hepatoma cell line, n4mBid, that supports high level of HCV infection and undergoes 
massive cell-death in response to HCV infection (97). The n4mBid cell line is a 
derivative of Huh 7.5, a cell line selected for its ability to support high levels of HCV 
replication(98). N4mBid contains  a modified pro-apoptotic protein BH3 interacting 
domain death agonist (mBid) that is cleaved and activated by the HCV protease NS3-
4A(99).  
 
To select for anti-HCV GSEs, we transduced n4mBid cells with genetic libraries 
comprising a fragmented HCV genome and infected the transduced cell population with 
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cell culture-produced HCV (HCVcc). We hypothesized that, among the transduced 
n4mBid cell population, cells harboring HCV-neutral and pro-HCV genetic fragments 
will succumb to the HCV cytopathic effect and be gradually eliminated from the 
population, while cells harboring anti-HCV GSEs will resist the HCV cytopathic effect 
and gradually dominate the surviving cell population after several rounds of selection. 
As we will describe below, this led to the selection of an anti-HCV protein we call B1. 
 
1.4 Cell penetrating proteins 
Intracellular delivery of large, therapeutic biomolecules poses a significant challenge. 
Effective delivery entails not only crossing the outer cell membrane but transport and 
release of therapeutic cargo to cellular loci conducive to the attainment of a therapeutic 
effect. Several lipid-, polymeric- and inorganic-based vehicles for intracellular delivery  
of proteins and nucleic acids have been reported, including cationic lipids (100-102), 
polyethylenimine (PEI) (103, 104), carbon nanotubes (105-107), gold nanoparticles 
(108-110), and nanocapsules (111, 112).  
 
The discovery that HIV Tat was capable of freely moving across the cell membrane 
inadvertently began a revolution of sorts in the field of protein transduction (113). Tat, 
which functions as a trans-activator of transcription of HIV genes, was shown to enter 
non-HIV infected cells, and eventually translocate into their nuclei (113). This discovery 
made Tat the first cell penetrating protein (CPP). Subsequent studies showed that an 
arginine–rich motif in Tat (GRKKRRQRRR) is responsible for cell-penetration (114). 
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This motif has been subjected to exhaustive analysis which lead to incremental 
improvements in its cell transduction capability (115, 116). Importantly, it was shown 
that fusing this Tat peptide to target proteins mediated the intracellular delivery of these 
proteins (117-120). Since then, a number of natural proteins have been found to have the 
capacity to penetrate cells, including the Antennapedia protein (Antp) from Drosophila 
(121, 122), VP22 protein from herpes simplex virus (123) and CaP from Brome mosaic 
virus(124). Similarly, several artificial CPPs have been created for protein and nucleic 
delivery, including highly positively charged peptides and proteins (e.g. poly arginine 
(125), supercharged +36 GFP (126) and related proteins (127)) and amphipathic peptides 
(e.g. Pep–1 (128), CADY (129)). Recently, an important discovery was made by the Liu 
group, who showed that many positively charged human proteins are also capable of 
cellular transduction(127). This study highlighted the importance of the ratio of positive 
charge and the molecular weight of each protein to efficient cellular transduction. The 
cellular uptake mechanisms of these CPPs are not yet fully understood, but many are 
believed to be internalized through endocytic pathways (130, 131). 
 
In spite of their relatively high synthesis cost, cellular penetrating proteins are 
therapeutically relevant as gene or drug delivery agents. This both due to their relatively 
lack of intrinsic toxicity when compared with more traditional lipid based transfection 
reagents, and their potential to transduce cells previously determined to be problematic 
for traditional transfection reagents. 
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Several candidate peptide-delivered therapeutics have been developed, some of which 
are currently in clinical trials for a wide range of ailments including keloid scarring, 
myocardial infarction, hearing loss, wrinkles, cancer and psoriasis (132-138). One such 
therapeutic made use of a fusion of the Tat protein transduction domain and a positively 
charged poly-lysine motif in order to deliver a Botulinum Toxin Type A (BOTOX) 
analog across the skin without the need for painful injections (133). Another used a 
modified TAT ptd (called PTD4) fused to a C terminal peptide from heat shock-related 
protein HSP20 (139). This fusion protein, called AZX100, showed some promise in 
clinical trials aimed at treating keloid scarring(133). 
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2. INTRACELLULAR B1 INHIBITS JC1 HCV REPLICATION  
 
2.1 Overview 
Hepatitis C virus (HCV) currently affects ~5% of the world’s population and has 
relatively limited treatment options for infected patients. Genetic suppressor elements 
(GSE) derived from a gene or genome of interest can act as transdominant inhibitor of a 
particular biology function presumably by binding to and blocking an essential 
interaction surface for protein activity. Taking advantage of hepatoma cell line n4mBid, 
that supports all stages of the HCV life cycle and strongly report HCV infection by a 
cell-death phenotype, we developed an iterative selection/enrichment strategy for the 
identification of GSE against HCV.  Using this strategy, a library expressing random 
fragments of the HCV genome was screened for sequences able to suppress HCV 
infection. A 244 amino acid gene fragment, B1, was strongly enriched after 5 rounds of 
selection. Surprisingly, B1 is derived from a single-base frameshift of the enhanced 
green fluorescent protein (eGFP) which was used as filler during library cloning. B1 has 
a very high net positive charge of 43 at neutral pH and a high charge-to-mass (kDa) ratio 
of 1.5. We show that B1 expression specifically inhibits HCV replication. In addition, 
five B1 fragments with progressive truncation at the C-terminus all retain significant 
ability to inhibit HCV, suggesting that the high positive charge, rather than a particular 
motif in B1, is likely responsible for the anti-HCV activity. This study reports a new 
methodology for HCV inhibitor screening and points to the anti-HCV potential of 
positively charged proteins/peptides.  
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2.2 Introduction 
Hepatitis C virus (HCV) is a single-stranded, enveloped, positive-sense RNA virus of 
the Flaviviridae family (1). HCV exhibits a high mutation rate and exists as a 
quasispecies in a single patient (11). Six major genotypes and numerous subtypes of 
HCV have been identified around the world (13). HCV infection affects over 180 
million people worldwide (2) and is the leading cause of cirrhosis and cancer of the 
liver(140, 141). HCV induced end-stage liver disease is the leading indication for liver 
transplantation in developed countries (3).  
 
Until recently the only approved HCV therapy involved a 24 or 48 week regimen of 
combination therapy involving pegylated interferon alpha and ribavirin (4, 142). 
Interferon alpha-ribavirin mono-treatment is costly, time-consuming and associated with 
serious and debilitating side effects such as depression, fatigue and flu-like symptoms (5, 
6), resulting in many patients being unable to complete the therapy. In addition, only 
50% of treated patients infected with the most common genotype achieved sustained 
virological response (SVR) after receiving interferon-alpha-ribavirin therapy(7).  Recent 
pharmacological advances have led to the development and approval of two new drugs, 
boceprevir and telaprevir, which greatly improve the treatment response to up to 79% of 
the patients (60, 61). However, molecules that target specific viral proteins, including 
boceprevir, telaprevir and most of those in advanced clinical development, tend to foster 
drug-resistant variants (143, 144). 
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Genetic suppressor elements (GSEs) are short, biologically active gene fragments 
derived from a gene or genome of interest that inhibit the function of the associated gene 
or protein (93, 145). GSEs can exert their inhibitory effect as antisense RNAs, structural 
RNAs, or peptide/protein fragments that act as transdominant-negative mutants by 
binding to and blocking an interaction surface essential for protein activity. A significant 
feature of GSE technology is that it does not require any previous knowledge of the 
target gene(s)/protein(s) or the type of inhibitor (antisense RNAs, RNA decoys or 
transdominant mutants) that will most potently suppress the function of a specific gene. 
For example, GSE technology has been used to identify previously unknown viral genes 
that are essential for the infectious cycle of bacteriophage lambda, highlighting the 
power of the GSE approach for uncovering new biological information even in a very 
thoroughly investigated system (146). Other successes of GSE selection include the 
elucidation of human immunodeficiency virus type 1 (HIV-1) latency(93), bovine viral 
diarrhea virus entry(94), tumor suppressor genes(147), genes that mediate cellular 
sensitivity to anticancer drugs(148, 149), regulators of transcription(150), and potential 
anticancer(151) and antiviral(152) targets.  
 
In addition to their role as tools for studying viruses, GSEs are potential therapeutic 
agents. GSEs have been found that decrease viral loads of bovine viral diarrhea virus 
(BVDV) by 100- to 1000-fold(94), a potency on par with some of the best BVDV 
antiviral candidates in preclinical and clinical trials (153). Even if the GSEs themselves 
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are not ideal drugs, suppressor elements can serve as templates for the creation of small 
molecule mimetics, which can in turn be used as potent antivirals.  
 
In this section we aimed to identify GSEs with anti-HCV activity. Using a previously 
developed hepatoma cell line, n4mBid, that reports HCV infection by a cell-death 
phenotype, we developed an iteratively selection strategy which gradually enriches anti-
HCV genetic fragments that confer resistance to HCV-induced cell death. Surprisingly, 
the most strongly enriched element, B1, is a 244 amino acid protein derived from a 
frame shifted enhanced green fluorescent protein (eGFP)(154) that was used as a filler 
during library cloning. B1 has a high net positive charge of 43 at pH 7, leading to a 
charge to molecular weight ratio of 1.5. B1 also possesses strong ability to delivery 
protein/nucleic acid cargo into the mammalian cell cytosol (section 3). We show here 
that B1 is able to inhibit HCV replication when expressed intracellularly and the 
inhibitory effect is largely mediated by its overall charge. 
 
2.3 Results 
2.3.1 GSE screens to identify genes involved in HCV infection  
A schematic for GSE selection in mammalian cells is shown in Figure 2.1. Random 
DNA fragments of 100-200bp were obtained by DNaseI digestion of a plasmid encoding 
full-length Jc1 HCV(38). These fragments were first polished to form blunt ends and 
then cloned into retroviral vector pV1 previously digested with restriction enzyme PmeI.   
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Figure 2.1. Overview of GSE selection. (A) Selection scheme. Randomly fragmented 
libraries were prepared by limited digestion of the HCV genome and fragments of 100-
200 bp were cloned into pV1 lentiviral vector and packaged into VSV-G pseudotyped 
lentiviral particles. Library pseudoparticles were delivered into n4mBid cells such that 
each library fragment was expressed in at least 1000 cells. These cells were then infected 
with HCV to induce cytotoxicity until <10% of the initial cell population remained 
viable. The specific HCV inhibitor 2’C-MA was then added to rescue the remaining 
surviving cells. Library fragments were repackaged by transfecting the surviving cells 
with plasmids encoding VSV-G and HIV gag-pol. (B) The percentage of surviving cells 
after each round of selection. (C) Gel image of cDNA insert harvested from repackaged 
pseudoparticles. 
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pV1 is a minimal HIV-1 provirus lacking most HIV genes except for all necessary cis 
acting sequences such as Tat, Rev and Vpu ORF(155). The Nef gene was also deleted in 
pV1, and replaced by a cloning site for the insertion and expression of the cDNA 
interest. The fragment library is transcribed from the viral LTR. We chose the pV1 for 
library expression because viral particles can be repackaged from pV1-transduced cells 
when these cells are supplemented with envelope glycoprotein and HIV gag-pol, 
facilitating the iterative library screening through cyclic packaging(19).  
We chose to express the fragmented library as C-terminal fusions to the transmembrane 
anchor of HCV NS4A (NS4Am) (156). Since HCV has been shown to replicate in 
replication complexes in association with the lipid raft membrane(157, 158), and HCV 
nonstructural (NS) proteins have been detected around lipid droplets in most HCV-
permissive cells(159), attachment of the membrane-anchoring domains from HCV NS 
proteins to library fragments is designed to facilitate the interaction of the library 
fragments with viral/host factors located in the vicinity of the replication complexes, 
thus increasing the likelihood of identifying genetic suppressor elements from the 
library. 
 
The random fragment library was prepared in lentiviral packaging cells and transferred 
to HCV reporter cell line n4mBid at a low multiplicity of infection (MOI) so that most 
transduced cells receive only one library fragment. The n4mBid cells contain a modified 
version of the pro-apoptotic protein Bid (mBid) and is able to induce apoptosis upon 
intracellular expression of HCV serine protease NS3-4A (97). Two days later, after the 
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expression of fragment library is established, these cells were infected with Jc1 HCVcc 
(MOI ~1) (38)and cultured until >90% of the cells succumbed to the induced cytopathic 
effect or up to 9 days. The surviving cells were ‘cured’ of any ongoing HCV infection by 
treatment with nucleoside analog 2’C-MA (1 µM) (160). Library fragments present in 
the surviving cells were repackaged by transfecting these cells with plasmid encoding 
VSV-G envelope protein. Repackaged lentiviruses were used in the next round of 
selection following the same procedure (Figure 2.1A). In some cases, the repackaged 
viruses were amplified in 293T cells to increase the viral titer prior to the next round of 
selection.  
 
In total, we screened a random library containing an estimated 12, 000 individual 
fragments. For a library based on a fragmented retroviral HIV genome, the frequency of 
active perturbations (i.e. desirable GSE molecules) was estimated to be ~1/6000(93). As 
shown in Figure 2.1B, the time it takes for the cytopathic phenotype to be displayed, as 
well as the percentage of surviving cells at the end of selection period, increased with 
each successive round of selection, indicating that some library fragments able to inhibit 
HCV-induced apoptosis were being enriched. At the end of the fifth round, library 
fragments were recovered from the repackaged lentivirus and the insert cDNA were 
synthesized via RT-PCR. We observed a significant enrichment of a fragment of ~800 
bp, and several fragments with sizes below 500 bp (Figure 2.1C). The 800 bp fragment 
was recovered and named B1 for convenience. Sequencing analysis showed that B1 is 
the product of a frameshift caused by an unintended single-base insertion preceding the 
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eGFP gene. Frameshifts in coding sequences typically yield very short polypeptides due 
to the concomitant introduction of new stop codons, but B1 contains 244 amino acids  
 
 
 
Figure 2.2. B1 nucleotide and amino acid sequence. Image showing comparative 
nucleotide and amino acid sequence of B1 and eGFP. Insertion which lead to the frame 
shift which generated B1 is shown in red. 
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and has a large positive charge of +43, making it similar in size to the original eGFP 
(238 amino acids). A protein database search of B1 using NCBI BLAST returned no 
matches, indicating no known homologs of B1. The eGFP gene is codon-optimized for 
expression in mammalian cells (154), and shares 71% nucleotide homology with the 
wild-type green fluorescent protein (GFP) from the jellyfish Aequorea Victoria (154, 
161, 162) (Figure 2.2). Introduction of the same frameshift mutation into the original 
GFP sequence yields a translated sequence of only one amino acid. Most of the smaller 
enriched fragments shown in Figure 2.1C correspond to a region near the C-terminal of 
HCV E2 (Figure 2.3). 
 
To confirm the expression of full-length B1 in Huh-7.5 cells, we constructed Flag-
tagged B1 (Construct 3 & 4, Table 2.1). As shown in Figure 2.4A, the full length B1 is 
expressed both with and without the NS4Am anchor. The expression levels of the Flag-
NS4Am-B1 appeared to be slightly lower than that of Flag-B1. We next determined the 
intracellular localization of both constructs using confocal microscopy. It was expected 
that Flag-NS4Am-B1 to be localized to the endoplasmic reticulum (ER) due to the 
presence of NS4Am membrane anchor. However, both Flag-NS4Am-B1 and Flag-B1 
appeared to be predominantly localized to the cell nucleus and concentrated in nucleolar 
regions (Figure 2.4B). Since no known nuclear localization signal is present in B1, we 
speculate that the nuclear localization may due to its interaction with negatively charged 
genomic DNA during cell division.  
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Figure 2.3. E2-derived isolated fragment analysis. A.E2-derived fragment sequence 
alignment. Additional fragments isolated after the library selection were aligned with 
HCV J6 E2. Fragments matched 60 bases near the C-terminal of E2 (nucleotides 2430-
2490). Bases showing complete homology among all sequences are highlighted in blue. 
The first base in each fragment is highlighted in red (start codons not shown). Bases 
remaining from original PmeI site are underlined. All fragments are -1 frame-shifted 
with the exception of MA-6 and MA-20.B. Table showing net charge and 
charge:MW(kDa) ratios of each peptide. *Indicates non-frame-shifted peptides.  
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Number Name 
Molecular 
weight (kDa) Expression vectors 
1 NS4Am-B1 30.6 pV1, pLenti6 
2 B1 28.4 pV1, pLenti6 
3 
Flag-NS4Am-
B1 33.3 pZsGreen (pTRIP) 
4 Flag-B1 31.1 pZsGreen (pTRIP) 
5 NS4Am-B2 17.8 pV1  
6 NS4Am-B3 14.7 pV1  
7 NS4Am-B4 13.2 pV1  
8 NS4Am-B5 10.7 pV1  
9 NS4Am-B6 6 pV1  
10  +36GFP 28.4 pV1  
 
 
Table 2.1. Protein constructs and vectors used in this section.  
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Figure 2.4. Expression of B1 in Huh 7.5 cells. A. Western blot of Flag-NS4Am-B1 (N-
B1) and Flag-B1. B Confocal microscope image of Huh-7.5 cells transduced with Flag-
NS4Am-B1 or Flag-B1 after immunohistochemical staining with anti-flag antibody.  
 
 
2.3.2 Intracellular B1 inhibits HCV infection 
To confirm the ability of B1 to confer HCV inhibition, the sequences of B1, NS4Am-B1 
or eGFP were cloned into pLenti6 provirus and packaged into pseudoparticles used to 
transduce naïve Huh-7.5 cells at MOI ~1. After selection with blasticidin, the resulting 
cell population were infected with Jc1 Gluc HCVcc (163) or HIV-1 lentivirus 
pseudotyped with envelope protein from H77 HCV (23) or vesicular stomatitis virus 
(VSV) (164). As shown in Figure 2.5A, cells expressing either NS4Am-B1 or B1 
showed significantly reduced infection level of Jc1 Gluc HCVcc when compared to that 
expressing eGFP, confirming the ability of B1 to inhibit HCV infection. No inhibition 
was observed in cells transduced with pseudotyped lentiviruses  
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Figure 2.5. B1 inhibits HCV infection. A. Cells expressing B1 or NS4Am B1 have 
reduced HCV infection level. Huh 7.5 cells were transduced with lentiviral 
pseudoparticles encoding eGFP, NS4Am-B1 or B1 prior to infection with Jc1 Gluc 
HCVcc (MOI <0.1), H77 HCVpp (10-fold dilution) or VSV-Gpp (500-fold dilution) for 
12 hours. The supernatant Gluc activity was quantified 24 hours later and used as 
indication of HCV infection level. Error bars represent the standard deviation of 
duplicate wells in two independent experiments. B. Cells expressing NS4Am-B1 have 
reduced HCV replication level. Huh 7.5 cells were transduced with lentiviral 
pseudoparticles expressing NS4Am-GFP or NS4Am-B1 at MOI 4. 48 hours later, these 
cells were electroporated with full length Jc1 Gluc HCVcc, or JFH Gluc replicon 
replicon HCV RNA. Intracellular HCV RNA levels were quantified 48 hours later using 
qRT-PCR. Error bars represent standard deviations of duplicate wells from two 
independent experiments. C. B1 does not inhibit HCV translation. Naïve Huh-7.5 cells 
or cells populations expressing NS4Am-B1 (as in B) were electroporated with Jc1 Gluc 
HCVcc or JFH Gluc HCV replicon RNA. HCV translation was quantified by measuring 
the activity of secreted Gluc 5 hours later. D. B1 does not inhibit SINV infection. BHK-J 
cells were transduced with lentiviral pseudoparticles expressing NS4Am-B1 or NS4Am 
alone at MOI ~4. Two days later, cells were infected with SINV for 12 hours and 
thoroughly washed. Infectious SINV in the supernatant collected 48 hours later were 
quantified by plaque assay. Error bars represent standard deviations of duplicate wells 
from two independent experiments. 
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regardless of the envelope protein, suggesting that B1 does not affect the entry step of 
HCV infection or lentiviral transduction.  
 
Since B1 appears to be predominantly located in the nucleus, and some nuclear factors 
are required for HCV replication (165-167), we next considered whether B1 inhibits 
HCV replication. Cell populations expressing NS4Am-eGFP or NS4Am-B1 were 
electroporated with RNA encoding either full length Jc1 Gluc HCVcc(38) or JFH Gluc 
HCV subgenomic replicon(168). The amount of intracellular HCV RNA was quantified 
48 hours post electroporation by qRT-PCR. Similar levels of inhibition were observed in 
cells electroporated with Jc1 Gluc HCVcc(38) (Figure 2.5B) and in cells infected with 
the same virus (Figure 2.5A). However, a much weaker but significant level of inhibition 
was observed with the JFH Gluc HCV replicon(168). The stronger inhibition seen in Jc1 
Gluc HCVcc(38) may, in part, be due to the amplification of effects from multiple 
rounds of infection.  
 
Next, we considered whether B1 might inhibit the translation/processing of HCV 
because 1) B1 was found to strongly associate with mRNA due to its high positive 
charge (section 3) and 2) B1 primarily localizes in the nucleus and HCV translation is 
potentially modulated by nuclear factors(165, 166). Cell populations expressing 
NS4Am-GFP or NS4Am-B1 were transfected with RNA expressing the full length Jc1 
Gluc HCVcc (38) or the JFH Gluc subgenomic replicon(168). In the Jc1 HCVcc 
construct, the reporter Gluc gene was inserted between p7 and NS2 while in the replicon 
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construct, the Gluc is translated directly from the JFH HCV IRES. HCV IRES-mediated 
translation was quantified based on reporter activity measured at 5 hours post 
transfection (prior to the onset of replication (169)). No inhibition of Jc1 or JFH 
translation was observed in cells expressing (Figure 2.5C), indicating that B1 does not 
affect IRES-mediated translation. 
 
Since B1 does not affect lentiviral transduction (Figure 2.5A), suggesting that B1 may 
not upregulate non-specific antiviral response mechanisms such as the interferon 
pathway or the unfolded protein response (170, 171). To confirm that B1 does not 
activate the innate antiviral machinery, we determined the ability of B1 to inhibit the 
infection of Sindbis Virus (SINV), a closely related positive sense RNA virus belonging 
to the Alphavirus genus(172). As anticipated, no inhibition of SINV was observed in 
cells expressing B1 (Figure 2.5D). 
 
2.3.3 B1 fragments retain anti-HCV activity 
Next, we decided to determine whether a specific domain/region in B1 is responsible for 
the anti-HCV activity. B1 is progressively truncated at the C-terminus to form shorter 
B2-6 (Figure 2.6A). The choice of truncation site is guided by the secondary structure 
predicted by the GOR4 algorithm(173). These truncated B1 fragments were cloned into 
pV1 lentiviral vector and packaged into lentiviruses. Huh-7.5 cell populations expressing 
the truncated B1 fragments were challenged with Jc1 Gluc HCVcc at MOI <0.1 and the  
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Figure 2.6. Truncated B1 retains significant anti-HCV activity. A. B1 was 
progressively truncated from the C-terminus to form B2-B6 based on secondary 
structure predicted by GOR4 algorithm(173). B. Anti-HCV activity of B1-B6. Huh-7.5 
cells were transduced with lentiviral pseudoparticles encoding the indicated constructs at 
MOI ~4. 48 hours later, these cells were infected overnight with Jc1 Gluc HCVcc (MOI 
<0.1). Supernatant Gluc activities were quantified 48 hours later and used as indication 
of HCV infection level. Error bars represent the standard deviation of duplicate wells 
from two independent experiments.  
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 HCV infection levels were quantified 3 days post infection. All shortened B1 constructs 
appear to significantly inhibit HCV infection to a level similar to the full-length B1 
(Figure 2.6B), indicating that no specific region/domain in B1 is singly responsible for 
HCV inhibition. Fragments with a positive charge above 16 all appear to have similar 
anti-HCV activity, while B6, the shortest fragment with a lower predicted charge of +11, 
showed slightly reduced anti-HCV activity. The negative control protein eGFP, with a 
predicted net charge of -8, showed no anti-HCV activity.  
 
2.3.4 Intracellular +36GFP is poorly expressed and does not inhibit HCV infection 
Since the HCV inhibition of B1 appears to be due to its charge, we tested the potential 
anti-HCV activity of one of another proteins, +36 GFP that has a similar positive charge 
as NS4Am-B1 (+39).  Fluorescent imaging of intracellular +36GFP indicated that it was 
predominantly localized in the cell nucleus, similar to B1 (Figure 2.7A). However, even 
after high MOI transduction (up to MOI 10), only a small percentage of the transduced 
cells showed detectable +36GFP expression (~20%) (Figure 2.7B). Consequently, no 
HCV inhibition was observed in cells expressing +36GFP (Figure 2.7C).  
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Figure 2.7. Intracellular +36GFP does not inhibit HCV infection. Huh 7 cells were 
transduced with lentiviral pseudoparticles expressing indicated constructs at MOI ~10. It 
was noted that using Huh 7 cells resulted in better expression of the +36GFP construct.  
Two days later, cells were infected with Jc1 Gluc HCVcc at <0.1 MOI for 12 hours. Cell 
supernatants were collected 48 hours post infection. At this time +36GFP expression was 
visualized with a fluorescent microscope (A). After imaging, cells were resuspended and 
the percentage +36GFP-expressing cells quantified with flow cytometry (B). HCV 
infection levels were quantified based on secreted Gluc levels in the collected 
supernatants (C).Error bars represent standard deviations of duplicate wells in two 
independent experiments. 
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2.3.5 Purified +36GFP but not GFP-L-B1 inhibits HCV infection 
Although +36GFP is poorly expressed by Huh 7.5 cells, it has been shown to have 
significant cell transduction activity in mammalian cells (126). In addition, we also 
showed that purified B1 protein also has significant cell transduction activity (174). 
These observations made it possible to circumvent the lack of expression of +36GFP in 
Huh 7.5 cells, by treating cells with purified +36GFP. As shown in Figure 2.8A, cells 
treated with at least 0.5 µM +36GFP significantly inhibited Jc1 HCV infection. In 
addition, +36GFP did not inhibit H77 HCVpp entry (Figure 2.8B). In contrast, treating 
cells with purified GFP-L-B1 protein prior to and during HCV infection did not result in 
HCV inhibition (Figure 2.8). 
 
2.4 Discussion 
In this section we report the development of a method for identifying genetic suppressor 
elements of HCV. Despite recent advances in direct acting antivirals (DAAs) against 
HCV, there remain critical needs for new HCV inhibitors with novel antiviral 
mechanism of action. The screening method we developed takes advantage of a 
hepatoma cell line previously developed in our laboratory, n4mBid, which supports the 
entire HCV life-cycle and effectively reports HCV infection via a cell death 
phenotype(97). A randomly fragmented HCV genomic library was delivered to n4mBid 
cells via lentiviral transduction. Transduced cells were subsequently challenged with Jc1 
HCVcc (38). The surviving cells were pooled and GSEs from these cells were harvested 
and repackaged, and used in subsequent rounds of selection and enrichment. 
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Figure 2.8. Purified +36GFP inhibits HCV infection. A. Anti-HCV activity of 
recombinant positively charged proteins. Huh 7.5 cells infected with Jc1 Gluc HCVcc in 
the presence of indicated concentrations of GFP-L-B1 or +36GFP for 12 hours. After 
infections cells were washed and protein dilutions replaced. HCV infection in each cell 
population was characterized based on secreted Gluc levels measured 48 hours later. 
HCV infection was inhibited by +36GFP but not GFP-L-B1. There was no significant 
inhibition of VSV-Gpp infection in these cells. Error bars represent the standard 
deviation of duplicate wells in two independent experiments. B. Anti-HCVpp activity of 
recombinant positively charged proteins. Huh 7.5 cells infected with H77pp or VSV-G 
in the presence of indicated concentrations of GFP-L-B1 or +36GFP for 12 hours. 
H77pp or VSV-Gpp infection in each cell population was characterized based on 
secreted Gluc levels measured 48 hours later.  GFP-l-B1 enhanced H77 and VSV-Gpp 
infection at higher concentrations. +36GFP inhibited VSV-Gpp infection but enhanced 
H77pp infection at higher concentrations. Error bars represent the standard deviation of 
duplicate wells in two independent experiments. 
  
 41 
 
After 5 rounds of screening, we identified B1, a 244 amino acid protein derived from a 
frame-shift in region immediately upstream of eGFP, a filler protein used during library 
cloning. B1 is a highly positively charged protein with significant cell-transduction 
capabilities and is capable of delivering cargo proteins and nucleic acids into the cytosol 
(section 3). In this section, we characterized the anti-HCV property of B1. The B1 
sequence was not intended to be a part of the original library, as eGFP was only a filler 
in the vector during the cloning. It is even rarer that B1 derived from a single nucleotide 
insertion in the primer region upstream of eGFP (Figure 2.3). We showed that B1 was 
expressed as a full length protein in Huh-7.5 cells (Figure 2.2A). Surprisingly, B1 
appeared to be almost exclusively localized in the nucleus even when fused to the NS4A 
membrane anchor (NS4Am) (Figure 2.2B). Despite its nuclear localization, both B1 and 
NS4Am-B1 exhibit similar anti-HCV potency (Figure 2.5A). Further characterization 
revealed that B1 does not affect HCV entry (Figure 2.5A) or virus production (data not 
shown) but specifically inhibits the replication step of the HCV life cycle (Figure 2.5B). 
Nuclear factors such as heterologous nuclear ribonucleoprotein L (hnRNP L)(165) and 
the nuclear La protein(166) have been demonstrated to affect HCV replication by 
upregulating HCV translation. This made it possible that B1 interacts with one of these 
such proteins, or their targets, leading to inhibition of viral translation. However, B1 
does not appear to inhibit IRES-mediated HCV translation (Figure 2.5C).   
 
To shed light on B1’s anti-HCV mechanism of action, a series of truncated B1 with 
progressive deletions at the C-terminus were generated. We have shown that the cell 
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transduction activity of B1 is not due to its charge and not a specific motif within the 
protein(174). We reasoned that, if the anti-HCV activity is derived from the overall 
charge of B1, a point would be reached where the charge on the construct is no longer 
sufficient to effect the same level of inhibition. Conversely, if the charge was irrelevant 
and the inhibition is due to a structural motif or specific region in B1, then once the 
motif was removed from the construct, its HCV inhibition should be completely 
abrogated. We generated truncated B1 with predicted net charges ranging from +11 to 
+39 and showed  that all these fragments, including the shortest fragment (35 amino 
acids  with a predicted charge of +11), retain significant anti-HCV activity, albeit the 
shortest fragment showed reduced anti-HCV potency (Figure 2.6B). This result suggests 
that the overall positive charge, rather than a specific motif, is likely responsible for the 
anti-HCV activity of B1.   
 
While positively charged proteins are relatively uncommon, many are expressed in 
mammalian cells (127). Previously, Liu and coworkers synthesized a series of highly 
charged GFP and showed that they can effectively transduce mammalian cells (126). We 
tested the potential anti-HCV activity of one of these charged proteins, +36 GFP that has 
a similar positive charge as NS4Am-B1 (+39).  However, +36GFP was poorly expressed 
in Huh 7.5 cells, and did not inhibit HCV infection (Figure 2.7). This poor expression 
seems to indicate that the host (mammalian) cells negatively regulate or control the 
expression of highly positively charged protein. Indeed due to their high tendency to 
interact with negatively charged nucleic acids, the presence of large amount of positively 
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charged proteins in the cytosol may negatively affect the cell cycle and growth. With this 
in mind, it is perhaps fortuitous that B1 expresses at a level sufficient to inhibit HCV 
without causing any unintended cytopathic effects.   
 
In addition to the B1, several shorter peptides were selected during the screen (Figure 
2.1C). Among the 20 clones we sequenced, 11 correspond to a region near the C-
terminal of HCV E2 (Figure 2.4A). These peptides had a modal charge of +3.9, and a 
charge to mass ratio of ~1 (Figure 2.4B). However, we were unable to observe consistent 
anti-HCV activity in cells expressing these fragments (data not shown). It would be 
expected that, based on results obtained with B1 and their enrichment during selection, 
these fragments should also have anti-HCV activity. However, due to their small sizes 
and low charges, their anti-HCV potencies are expected to be significantly weaker than 
that of B1. This, in addition to the fact that positively charged proteins are weakly 
expressed in these cells, will have undoubtedly contributed to our inability to observe 
any significant inhibition effect.  
 
Taken at face value, the anti-HCV activity of B1 is comparable to the antiviral effects of 
defensins. Defensins are short (less than 100 amino acids), positively charged peptides 
that contain six cysteine residues(175). Defensins are broad-spectrum antimicrobials and 
have been shown to be active against bacteria, fungi and some enveloped viruses (176-
180). The antiviral activity of defensing is largely attributed to its positive charge (177). 
However, defensins act directly on extracellular viruses while B1 inhibits intracellular 
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HCV replication. Treating cells with purified B1 protein prior to or during HCV 
infection did not result in HCV inhibition (Figure 2.8). Extracellularly delivered B1 
exhibited punctate structure in the para-nucleus region (section 3), somewhat similar to 
that of extracellularly delivered +36 GFP (126). However, intracellularly expressed B1 
appeared to exclusively localize in the nucleus (Figure 2.2B). The difference in 
subcellular localization of B1 may be critical to its ability to inhibit HCV replication. 
Human alpha defensins 1-3 was found to act intracellularly to inhibit PKC signaling, 
which results in inhibition of HIV infection (181). However, no inhibition of 
pseudotyped lentivirus was observed in cells expressing B1 (Figure 2.5A), implying that 
B1 does not significantly inhibit PKC signaling and B1 does not function like a defensin 
in these cells. In contrast, extracellularly delivered +36GFP did significantly inhibit 
HCV and pseudotyped lentivirus infection (Figure 2.8). This implies that unlike B1, 
recombinant +36GFP may possess some defensin-like antiviral activity. 
 
In conclusion we have developed a new in vitro method for selecting GSEs against 
HCV. We identified a highly positively charged protein, B1, capable of inhibiting HCV 
replication. We showed that B1’s positive charge is likely responsible for its anti-HCV 
activity, as a truncated B1 construct with less positive charge showed weaker HCV 
inhibition. This is a novel mechanism for inhibiting HCV replication and may open 
doors to new HCV antiviral design and synthesis. In addition, this GSE selection method 
can be applied to other protein or peptide libraries in the continued search for new anti-
HCV factors.  
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2.5 Materials and methods 
2.5.1 Reagents, bacterial strains and cell lines  
TZM- bl cells were obtained from Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme 
Inc. through the NIH AIDS Reagent Program, Division of AIDS, NIAID. Huh 7 and 
Huh-7.5 cells were obtained from Prof. Charles Rice (Rockefeller University). 293T 
cells were purchased from Invitrogen. 
 
All cell lines were cultured in complete growth medium (Dulbecco’s Modified Eagle 
Medium (DMEM) containing 4500 mg/L glucose, 4.0 mM L- Glutamine, and 110 mg/L 
sodium pyruvate (Thermo Scientific HyClone, Logan, UT) supplemented with 10 % 
fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA) and 1X non- essential 
amino acids (Thermo Scientific HyClone, Logan, UT)). Escherichia coli strains DH5α 
and Stbl3 (Invitrogen) were used for recombinant DNA cloning. 
 
Biolux Gaussia Luciferase Assay Kit was purchased from New England Biolabs. 
Dulbecco's Phosphate- Buffered Saline (DPBS) was purchased from Thermo Scientific 
HyClone. OptiMEM and Lipofectamine 2000 were purchased from Invitrogen. Luria- 
Bertani (LB) broth, Mirus TransIT LT1 transfection reagent and ampicillin were 
obtained from Thermo Fisher Scientific. 0.25% trypsin- EDTA was from VWR 
International. All restriction enzymes, nucleases and polymerase were purchased from 
New England Biolabs. 
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2.5.2 Fragment library preparation 
Plasmid DNA encoding full-length Jc1-NFlag2 HCVcc (38) was digested with DNaseI 
at 16 °C for ~2 minutes to obtain an average fragments size between 100-200 bp. The 
digested DNA were extracted by phenol-chloroform following standard protocol, 
sequentially treated with Mung Bean Nuclease, T4 DNA polymerase and Klenow 
Fragments to form blunt ends, and phosphorylated using T4 Polynucletide Kinase. 
Blunted fragments were inserted into the pV1 lentiviral vector downstream of NS4A 
membrane anchoring domain (NS4Am). pV1 is a minimal HIV-1 provirus lacking most 
of the HIV genes except for essential cis-acting elements and the tat, rev and vpu genes 
(155). The vector backbone was prepared by digesting pV1-NS4Am-eGFP with PmeI to 
remove the eGFP insert and dephosphorylated using Antarctic Phosphotase. The ligation 
mixture was electroporated into E. coli DH5α. Colonies were pooled and cultured, and 
the plasmid DNA library (Lib4) was isolated. 
 
2.5.3 Pseudoparticle production and titering 
Lib4 expressing pseudoparticles (Lib4pp) were generated based on a procedure 
described previously (90). Briefly, 293T cells were transfected with a 2:2:1 mass ratio of 
plasmids encoding HIV gag-pol, vesicular stomatitis virus glycoprotein (VSV-G), and 
Lib4 using TransIT-LT1 transfection reagent(19). Cell supernatants containing VSV-G 
coated, Lib4pp were collected 48 hours later, filtered and stored at -80 C until use. 
Collected Lib4pp were titered in TZM-bl indicator cells. TZM-bl cells were inoculated 
with serial dilutions of Lib4pp (10-1 - 10-6). 48 hours later cells were washed with DPBS, 
 47 
 
fixed in PBS/2% paraformaldehyde (PFA) and stained with X-Gal (VWR International). 
The TCID50 of the Lib4pp in TZM-bl were calculated using the method of Reed and 
Meunch(182). The titer determined in TZM-bl cells was correlated to that in Huh 7.5 
cells by comparing the infectivity of GFP expressing pseudoparticles (GFPpp) in both 
cell types. GFPpp was generated using the same protocol replacing Lib4 expressing 
plasmid with pTRIP-GFP(183). Huh 7.5 and TZM-bl cells were inoculated with serial 
dilutions of GFPpp (10-1 - 10-6). 48 hours later, Huh-7.5 cells were collected and 
analyzed with flow cytometry (FACScan flow cytometer, BD Biosciences) while 
infection of TZM-bl cells were analyzed as described above. The infectivity of the 
pseudoparticles was estimated based on infection at low multiplicity of infection (MOI) 
and correlated between these two cell lines. 
 
Lentivirus pseudotyped with envelope proteins from HCV H77 (H77pp) (23)and VSV-G 
(VSV-Gpp)(164) were generated from 293T cells as previously described (90). Both 
H77pp and VSV-Gpp harbor pTRIP-Gluc provirus. Briefly, 293T cells were transfected 
with a 1:4:1 mass ratio of HIV gag-pol, Gluc, and H77/VSV envelope expressing 
plasmid using TransIT-LT1 transfection reagent(19). Cell supernatants containing 
H77pp or VSVG-pp were collected 48 hours later, filtered and stored at -80 C until use.  
 
2.5.4 Library selection  
For each round of selection, a total 2.1 x 107 n4mBID cells were transduced with Lib4pp 
at MOI ~0.5. This allowed for the expression of each potential library fragment in at 
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least 1000 cells. Cells were cultured for 48 hours post transduction to allow for fragment 
expression. Next, these cells were challenged with Jc1 HCVcc at MOI~1, and cultured 
until less than 10% of cells remained viable or for up to 9 days. Surviving cells were 
‘rescued’ from HCV infection by treatment with HCV polymerase inhibitor 2’C-MA (1 
µM) for 72 hours. Library fragments in the surviving cells were recovered by 
transfecting these cells with plasmids encoding HIV gag-pol and VSV-G using Fugene-6 
transfection reagent (Promega). The Fugene-6 reagent was used here due to its low 
cytotoxicity in these cells. Cell supernatants containing VSV-G coated Lib4pp were 
collected 48 hours later, filtered and stored at -80 °C. Since Huh-7.5 cells do not have 
high transfection efficiency, Lip4pp repackaged from Huh-7.5 cells need to be amplified 
prior to the next round of selection. Briefly, 293T cells were first transduced with ten-
fold diluted Lib4pp. 48 hours later, these cells were transfected with plasmids encoding 
HIV gag-pol and VSV-G using Trans-IT LT1 transfection reagent (Mirus). Cell 
supernatants containing high titers of repackaged Lib4pp were collected 48 hours later, 
filtered and stored at -80 °C. This amplification step typically increases the lentiviral 
titer by ~100-fold. Recovered supernatants were titered in TZM-bl cells as described 
above and used for subsequent rounds of infection. After the final round of selection, 
viral RNA were isolated using RNeasy Mini Kit (Qiagen) and cDNA corresponding to 
the library fragment were amplified by RT-PCR (ImProm-II, Promega) using primers 
Lib4-F( 5’-ACG GCC TCT AGA ATG AGC-3’) and Lib4-R (5’- AGT GGC TAA GTC 
TAC AGC TG-3’) . Amplified fragments were analyzed on a 1.5% agarose gel.  
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2.5.5 Immunofluorescent imaging and Western blotting 
Huh 7.5 cells were seeded into wells of a glass chamber slide before being transduced 
with lentiviral pseudoparticles expressing Flag-tagged NS4Am-B1 and B1 (Constructs 
#3-4, Table 2.1). Two days post transduction, cells were fixed by incubating in PBS/2% 
PFA for 30 minutes at 4 °C, stained with mouse anti-Flag primary antibody (Genscript) 
and Alexa-Fluor 568-conjugated goat anti-mouse secondary antibody (Invitrogen), 
treated with anti-fade reagent (Promega) overnight and imaged using a Zeiss 510 Meta 
NLO Multiphoton microscope (Carl Zeiss Microscopy). 
 
For Western blotting, these cells were lysed with Renilla luciferase assay lysis buffer 
(Promega) two days post transduction cells. Cell lysates were subsequently combined 
with an equal volume of 2X SDS loading buffer and heated at 95 °C for five minutes. 
Samples were separated on a SDS-PAGE (12% acrylamide) and transferred to a PVDF 
membrane. After transfer, the membranes were stained mouse anti-Flag primary 
antibody (Genscript) and HRP-conjugated donkey anti-mouse secondary antibody 
(Jackson ImmunoResearch), developed using West Pico Chemiluminescent HRP 
substrate (Pierce) and visualized in a ChemiDoc-It (UVP) chemiluminescence imager. 
 
2.5.6 HCV infection assay 
To confirm the anti-HCV activity of B1, Huh-7.5 cells were transduced with pLenti6-
GFP/B1/NS4Am-B1pseudoparticles at low (<0.5) MOI, selected with blasticidin (10 
µg/mL) for 8 days and infected with Jc1 Gluc HCVcc (MOI <0.1), H77pp (diluted 10-
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fold) or VSV-Gpp (diluted 500-fold) for 12 hours. The cells were thoroughly washed 
with complete growth media to remove residual Gluc protein in the supernatant and the 
infection in each cell population was quantified by the amount of secreted Gluc in the 
supernatant 24 hours later.  
 
2.5.7 HCV replication and translation assay 
GFP or B1 construct expressing cells were electroporated with full length JC1 Gluc, or 
YSGR- JFH Gluc replicon(168) HCV RNA. At 5 hours post electroporation, HCV 
translation was quantified based on reporter Gluc activity in the cell supernatants (Figure 
2.5C). 48 hours post electroporation, cells were harvested and intracellular HCV RNA 
levels as quantified by qRT-PCR as described previously(90) (Figure 2.5B).  
 
2.5.8 SINV production and infection assay 
Infectious SINV was generated and titered in BHK-J cells as described previously (184). 
Briefly, 1 x 107 BHK-J cells were suspended in 400 µl DPBS and electroporated with 3 
µg SINV Toto1101 RNA(172) using an ECM 830 electroporator (Harvard Apparatus) at 
the following settings: 750 V, 99-μs pulse length, 5 pulses, 1.1-s interval. Cell 
supernatants were collected 24 hours post electroporation, filtered and stored at -80 °C. 
SINV titers were determined by infecting BHK-J cells with ten-fold serial dilutions of 
virus before carrying out a plaque assay 24 hours later. 
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To evaluate the ability of B1 to inhibit SINV, BHK-J cells were transduced with pV1-
NS4Am-eGFP/B1 (Table 2.1, construct 1)-expressing pseudoparticles at MOI ~4. 48 
hours later, these cells were infected overnight with SINV MOI ~10. Cell supernatants 
were collected 36 hours later upon cell lysis and the amount of infectious SINV in each 
supernatant were determined using plaque assays.  
 
2.5.9 Protein sequences 
Amino acids corresponding with the NS4Am sequence are highlighted in gray. Amino 
acids corresponding with the Flag tag used are highlighted in red. 
(1) NS4Am-B1 
MSTWVLAGGVLAAVAAYCLANWFKREQGRGAVHRGGAHPGRAGRRRKRPQ
VQRVRRGRGRCHLRQADPEVHLHHRQAARALAHPRDHPDLRRAVLQPLPRPHE
AARLLQVRHARRLRPGAHHLLQGRRQLQDPRRGEVRGRHPGEPHRAEGHRLQ
GGRQHPGAQAGVQLQQPQRLYHGRQAEERHQGELQDPPQHRGRQRAAHRPLP
AEHPHRRRPRAAARQPLPEHPVRPEQRPQREARSHGPAGVRDRRRDHSRHGRG
LN 
 
(2) B1  
MWFKREQGRGAVHRGGAHPGRAGRRRKRPQVQRVRRGRGRCHLRQADPEVH
LHHRQAARALAHPRDHPDLRRAVLQPLPRPHEAARLLQVRHARRLRPGAHHLL
QGRRQLQDPRRGEVRGRHPGEPHRAEGHRLQGGRQHPGAQAGVQLQQPQRLY
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HGRQAEERHQGELQDPPQHRGRQRAAHRPLPAEHPHRRRPRAAARQPLPEHPV
RPEQRPQREARSHGPAGVRDRRRDHSRHGRGLN 
 
(3) Flag-NS4Am-B1  
MDYKDHDGDYKDHDIDYKDDDDKSTWVLAGGVLAAVAAYCLANWFKREQG
RGAVHRGGAHPGRAGRRRKRPQVQRVRRGRGRCHLRQADPEVHLHHRQAAR
ALAHPRDHPDLRRAVLQPLPRPHEAARLLQVRHARRLRPGAHHLLQGRRQLQD
PRRGEVRGRHPGEPHRAEGHRLQGGRQHPGAQAGVQLQQPQRLYHGRQAEER
HQGELQDPPQHRGRQRAAHRPLPAEHPHRRRPRAAARQPLPEHPVRPEQRPQRE
ARSHGPAGVRDRRRDHSRHGRGLN 
 
(4) Flag-B1 
MDYKDHDGDYKDHDIDYKDDDDKWFKREQGRGAVHRGGAHPGRAGRRRKR
PQVQRVRRGRGRCHLRQADPEVHLHHRQAARALAHPRDHPDLRRAVLQPLPRP
HEAARLLQVRHARRLRPGAHHLLQGRRQLQDPRRGEVRGRHPGEPHRAEGHRL
QGGRQHPGAQAGVQLQQPQRLYHGRQAEERHQGELQDPPQHRGRQRAAHRPL
PAEHPHRRRPRAAARQPLPEHPVRPEQRPQREARSHGPAGVRDRRRDHSRHGR
GLN 
(5) NS4Am-B2  
MSTWVLAGGVLAAVAAYCLANWFKREQGRGAVHRGGAHPGRAGRRRKRPQ
VQRVRRGRGRCHLRQADPEVHLHHRQAARALAHPRDHPDLRRAVLQPLPRPHE
AARLLQVRHARRLRPGAHHLLQGRRQLQDPRRGEVRGRHPGEPHRAEGHRLQ 
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(6) NS4Am-B3 
MSTWVLAGGVLAAVAAYCLANWFKREQGRGAVHRGGAHPGRAGRRRKRPQ
VQRVRRGRGRCHLRQADPEVHLHHRQAARALAHPRDHPDLRRAVLQPLPRPHE
AARLLQVRHARRLRPGAHHLLQGRRQ 
 
(7) NS4Am-B4 
MSTWVLAGGVLAAVAAYCLANWFKREQGRGAVHRGGAHPGRAGRRRKRPQ
VQRVRRGRGRCHLRQADPEVHLHHRQAARALAHPRDHPDLRRAVLQPLPRPHE
AARLLQVRHARRL 
 
(8) NS4Am-B5  
MSTWVLAGGVLAAVAAYCLANWFKREQGRGAVHRGGAHPGRAGRRRKRPQ
VQRVRRGRGRCHLRQADPEVHLHHRQAARALAHPRDHPDLRRAVL 
 
(9) NS4Am-B6  
MSTWVLAGGVLAAVAAYCLANWFKREQGRGAVHRGGAHPGRAGRRRKRPQ
VQRVR 
 
(10) +36GFP  
MGHHHHHHGGASKGERLFRGKVPILVELKGDVNGHKFSVRGKGKGDATRGKL
TLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPKHMKRHDFFKSAMPKGYVQE
RTISFKKDGKYKTRAEVKFEGRTLVNRIKLKGRDFKEKGNILGHKLRYNFNSHK
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VYITADKRKNGIKAKFKIRHNVKDGSVQLADHYQQNTPIGRGPVLLPRNHYLST
RSKLSKDPKEKRDHMVLLEFVTAAGIKHGRDERYK 
 
2.5.10 Cloning 
All constructs used in this study are listed in Table 2.1. The 800 bp fragment shown in 
Figure 2.2C was gel purified and named NS4Am-B1 DNA for convenience. To generate 
pV1-B1 (construct 2), the B1 sequence was PCR amplified from the NS4Am-B1 DNA 
template using primers XbaI-B1-F (5’-CAT ACT TCT AGA ATG TGG TTT AAA 
CGT GAG CAA GG-3’) and Lib4-R. The PCR product was digested with XbaI and 
XhoI before ligation into the pV1 vector.  
To generate pLenti6-NS4Am-B1 the NS4Am-B1 sequence was amplified from the pv1-
NS4Am-B1 construct using primers BamHI-Lib4-F (5’- CAT ACT GGA TCC ATG 
TGG TTT AAA CGT GAG CAA GG-3’) and Lib4-R. Similarly to generate pLenti6-B1, 
the B1 sequence was PCR amplified from the NS4Am-B1 DNA template using primers 
BamHi-Lib4-F and Lib4-R. PCR products were digested with BamHI and XhoI before 
ligation into the pLenti6 vector. 
 
To generate pV1-NS4Am-B2, pV1-NS4Am-B3, pV1-NS4Am-B4, pV1-NS4Am-B5 and 
pV1-NS4Am-B6 (constructs 5-9),  the sequences were each PCR amplified from the 
NS4Am-B1 DNA using forward primer Lib4-F and reverse primers: B2-R (5’-GAT 
ATG CTC GAG CTA TTG AAG TCG ATG CCC TTC-3’); B3-R (5’-GAT ATG CTC 
GAG CTA TTG CCG TCG TCC TTG A-3’); B4-R (5’-GAT ATG CTC GAG CTA 
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TAG TCT TCG GGC ATG G-3’); B5-R (5’-GAT ATG CTC GAG CTA AAG CAC 
TGC ACG CCG TA-3’); B6-R (5’-GAT ATG CTC GAG CTA CCG GAC ACG CTG 
AAC TT-3’) respectively. The PCR products were digested with XbaI and XhoI before 
ligation into the pV1 vector.  
 
To generate pZsGreen-NS4Am-B1 (construct 3), the Flag-NS4Am-B1 sequence was 
PCR amplified from the NS4Am-B1 DNA using a forward primer Flag-NS4Am-B1-F 
(5’- CATGATTCTAGAATG GACTACAAAGACGACGACGACAAG 
AGCACGTGGGTCCTAGCT-3’), containing  the Flag-tag sequence at the 5’ end, and 
reverse primer B1-BamHI-R (5’- GTA TAG GGA TCC AGT GGC TAA GTC TAC 
AGC TG-3’). Similarly to generate pZsGreen-Flag-B1, the Flag-B1 sequence was 
amplified from the NS4Am-B1 DNA using a forward primer Flag-B1-F (5’- 
CATGATTCTAGAATG GACTACAAAGACGACGACGACAAG 
TGGTTTAAACGTGAGCAAGGG-3’), that added the Flag-Tag sequence to the 5’ end 
of the gene and reverse primer B1-BamHI-R. PCR products were digested with XbaI 
and BamHI before ligation into the pZsGreen vector (185), resulting in pZsGreen-Flag-
NS4Am-B1 and pZsGreen-Flag-B1. The pZsGreen lentiviral vector expresses the target 
gene and the GFP reporter as a single mRNA controlled by a CMV promoter. In 
ZsGreen the target gene translation is controlled by the 5’cap, while the GFP reporter 
translation is controlled by an EMCV IRES.  
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To generate pv1-+36 GFP (construct 10), the +36GFP was PCR amplified from the pET-
+36GFP plasmid (a generous gift from David Liu (Harvard University)) using forward 
primer +36GFP-F (5’- GCG TAG AGG ATC GAG ATC TC-3’) and reverse primer 
+36GFP-R (5’- CTC AAG ACC CGT TTA GAG GC-3’). The PCR product was 
digested with XbaI and XhoI before ligation into the pV1 vector. 
 
2.5.11 Protein expression and purification 
BL21 (DE3) cells were transformed with the expression plasmid and plated on a Luria–
Bertani (LB) agar plate containing 100 µg/mL ampicillin. The next day, a single colony 
was picked and cultured at 37°C with shaking at 250 rpm. At OD600 ~0.6, the cells were 
cooled to 18°C and isopropyl β–D–1–thiogalactopyranoside (IPTG, 0.5 mM) was added 
to the culture to induce protein expression. After overnight expression (~18 hours) at 
18°C, cells were harvested by centrifugation at 6000 x g and 4°C for 20 minutes and 
pellets were stored at –80 °C until use.  
 
For recombinant protein purification, cell pellets were resuspended in lysis buffer (500 
mM NaCl, 50 mM Tris, pH 8, 10 mL per 1 g wet cell pellet), and disrupted by sonication 
on ice (QSonica Misonix 200 (Qsonica), 1 second pulse 6 second pause for 3 minutes 10 
amp). Whole cell lysate was clarified by centrifugation at 20,000 x g for 20 minutes at 
4°C. Soluble cell lysates were loaded onto 5 mL Ni–NTA agarose beads (Qiagen). For 
constructs expressing B1 or +36GFP, the loaded resin was washed with lysis buffer 
supplemented with 150 mM imidazole and the product was eluted in lysis buffer 
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supplemented 500 mM imidazole. For all other constructs the loaded resin was washed 
with lysis buffer supplemented with 50 mM imidazole and the product was eluted in 
lysis buffer supplemented 150 mM imidazole. Purified protein samples were dialyzed 
overnight at 4°C into Buffer A (2 M NaCl, 2.7 mM KCl, 10 mM Na2HPO4.2H2O, 2 mM 
KH2PO4, pH 7.4). +36GFP was further purified by cation exchange chromatography 
using a GE HiTrap SP HP column (GE Biosciences, PA). Dialyzed proteins were diluted 
1:5 into PBS to reduce the salt concentration and then loaded onto the SP column. The 
column was washed with Buffer B (0.5 M NaCl, 2.7 mM KCl, 10 mM Na2HPO4.2H2O, 
2 mM KH2PO4, pH 7.4) and the target protein was eluted in Buffer A. Purified proteins 
were concentrated via ultracentrifugation through an Amicon 10 kDa MWCO 
centrifugal column (EMD Millipore). The final protein concentrations were determined 
using a Pierce Coomassie Plus Protein Assay Kit (Thermo Fisher Scientific).  
 
 
 
 
 
 
 58 
 
 3. RECOMBINANT B1 IS A CELL-TRANSDUCING PROTEIN  
 
3.1 Overview 
In this section we describe a new cell-penetrating protein, B1, capable of delivering 
conjugated proteins and nucleic acids into mammalian cells. B1 is a 244-amino-acid 
product of a single-base frameshift in the gene encoding enhanced green fluorescent 
protein (eGFP). The molecule has a net positive charge of 43 and a very high charge-to-
mass ratio of 1.5. eGFP-fused B1 potently penetrates both adherent and suspension cells 
with >80% of cells taking up the protein when exposed to concentrations as low as 1 
µM. The protein was found to cluster in the paranuclear region of TZM-bl cells. Most 
importantly, we show that B1 not only facilitates cellular uptake, but allows 
biomolecular cargo to reach sites of biological relevance. For example, baby hamster 
kidney cells underwent DNA recombination when exposed to B1-tagged Cre 
recombinase at protein concentrations as low as 2.5 µM, indicating potent nuclear 
delivery of functional protein cargos. Additionally, B1 delivers non-covalently 
conjugated RNA and DNA across the cell membrane to cytosolic and nuclear sites 
accessible to the cellular translation and transcription machinery, as gauged by detection 
of encoded reporter functions, with efficiency comparable to commercially available 
cationic lipid reagents. B1 appears to utilize cell-surface glycans and multiple competing 
endocytic pathways to enter and traffic through cells. These studies provide both a new 
tool for intracellular delivery of biomolecules and insights that could aid in the design of 
more effective cell penetrating proteins.  
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3.2 Introduction 
Intracellular targeting of large therapeutic biomolecules poses a significant challenge. 
Effective delivery entails not only crossing the outer cell membrane but transport and 
release of therapeutic cargo to cellular loci conducive to attainment of the therapeutic 
effect. Several lipid-, polymeric- and inorganic-based vehicles for intracellular delivery  
of proteins and nucleic acids exist, including cationic lipids (100-102), polyethylenimine 
(PEI) (103, 104), carbon nanotubes (105-107), gold nanoparticles (108-110), highly 
charged green fluorescent protein (GFP) (126, 186) and nanocapsules (111, 112). 
However, the field of intracellular delivery of large molecules is still in its infancy and 
major strides need to be made both in effectiveness of delivery and our understanding of 
the underlying mechanisms before this approach can be used in the clinic.  
 
The first cell penetrating polypeptide (CPP) identified was the HIV Tat protein, which is 
able to enter cells and translocate into the nucleus (113). The Tat protein transduction 
domain has been fused to many target proteins to mediate cellular delivery (117-120). 
Since then, a number of natural proteins have been found to have the capacity to 
penetrate cells, including the Antennapedia protein (Antp) from Drosophila (121, 122), 
VP22 protein from herpes simplex virus (123) and CaP from Brome mosaic virus(124). 
Similarly, several artificial CPPs have been created for protein and nucleic delivery, 
including highly positively charged peptides and proteins (e.g. poly arginine (125), 
supercharged +36 GFP (126) and related proteins (127)) and amphipathic peptides (e.g. 
Pep–1 (128), CADY (129)). The cellular uptake mechanism of these CPPs is not yet 
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fully understood, but many are believed to be internalized through endocytic pathways 
(130, 131).  
 
In this section, we describe the cell penetrating ability of B1. This study evaluates the 
effectiveness of B1 as a vehicle for intracellular delivery of two types of biomolecular 
payloads – genetically fused proteins and non-covalently conjugated nucleic acids. We 
demonstrate that B1 not only potently mediates cellular uptake of large molecules, but 
delivers the cargo to biologically relevant cellular sites. To our knowledge, the 
efficiency of mRNA delivery mediated by B1 is the highest reported for CPPs to date 
and is comparable to that mediated by commercially available cationic lipids. The ability 
of B1 to effectively deliver functional cargo to the cytosol may at least facilitate its use 
in in vitro stem cell engineering for which it is desirable to transiently deliver 
transcription factor(s) to cells to achieve cell fate reprograming(187).   
 
This study also provides insights into the mechanism of cell penetration by B1. We show 
that (1) cell-surface glycans and several cellular endocytic pathways play a role in 
cellular entry and cargo delivery by B1, and (2) the contribution of specific endocytic 
pathways to cellular entry versus functional cargo delivery by B1 can be significantly 
different. B1 penetrates cells through a mechanism distinct from that of another high-
positive-charge protein +36GFP as gauged from intracellular distribution and time-
/temperature-dependent cell penetration profiles. Thus, B1 represents a complementary 
addition to the current toolkit for intracellular delivery.  
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3.3 Results 
3.3.1 B1 penetrates mammalian cells and mediates cellular uptake of conjugated 
proteins  
Testing the cell transduction potential of B1 required the expression and purification of 
the recombinant protein. 6xHis-tagged B1 (6H-B1, Table 3.1) was expressed as a soluble 
protein in E. coli BL21(DE3) cells and purified via one-step immobilized-metal affinity 
chromatography (IMAC), although a very high concentration of imidazole (0.5–1 M) is 
needed to elute resin-bound B1 (Figure 3.1A). The yield of purified 6H-B1 was ~4 mg 
per liter of E. coli culture, with an estimated purity > 90%. To remove excess imidazole, 
6H-B1 was dialyzed in a modified PBS containing an increased concentration of NaCl (2 
M NaCl, 2.7 mM KCl, 10 mM KH2PO4, 10 mM Na2HPO4, pH 7.4). Dialysis of purified 
6H-B1 in unmodified PBS (containing 137 mM NaCl) yielded significant amounts of 
white precipitate in the dialysis tubing. Dialyzed 6H-B1 can be stored at 4°C for up to 2 
weeks without significant loss of protein activity, or at -80°C.  
 
To enable detection of intracellular B1, we fused the globular protein eGFP to the N-
terminus of B1 via a flexible linker to form GFP-L-B1 (Table 3.1). We purified GFP-L-
B1 by one-step IMAC, akin to our purification of B1 (Figure 3.1B). However, we noted 
the co-purification of a band at ~38 kDa that is presumed to be a truncation of 6 His 
tagged-GFP and part of the N terminal region of B1. Purified GFP-L-B1 exhibited 
greatly improved stability compared to B1. The purified protein can be easily dialyzed 
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with minimal precipitation and the dialyzed protein can be stored at 4°C for a few 
months without loss of activity. GFP-L-B1 is non-toxic to mammalian cells (Figure  
 
 
Number Short Name Short sequence 
Molecular weight 
(kDa) 
1 6H-B1 HHHHHH-B1 30.3 
2 GFP-L-B1 HHHHHH-GFP-2X(GGGGS)-B1 60.2 
3 GFP-L-B1-F HHHHHH-GFP-2X(GGGGS)-B1(F) 41.5 
4 GFP-L-B1-M 
HHHHHH-GFP-2X(GGGGS)-
B1(M) 41.2 
5 GFP-L-B1-R HHHHHH-GFP-2X(GGGGS)-B1(R) 38.7 
6 
mCherry-L-
B1 HHHHHH-mCherry-8X(GGS)-B1 58.9 
7 
mCherry-L-
R10 
HHHHHH-mCherry-8X(GGS)-
10X(R ) 32.4 
8 
mCherry-L-
TAT 
HHHHHH-mCherry-8X(GGS)-
TAT(ptd) 32.2 
9 Cre-L-B1 HHHHHH-Cre-8X(GGS)-B1 72.2 
10 Cre-L-R10 HHHHHH-Cre-8X(GGS)-10X(R ) 43.4 
 
Table 3.1. Protein constructs used in this section.  
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Figure 3.1. Purification of recombinant B1. A. E. coli expressing recombinant 6H-B1 
were suspended in lysis buffer (500 mM NaCl, 50 mM Tris at pH 8) and  lysed using 
French press (model number). The soluble lysate containing 6H-B1 was loaded onto a 
Ni-NTA agarose column. Impurities were removed by extensive washing with Lysis 
Buffer supplemented with 150 mM imidazole. 6H-B1 was eluted from the column with 
lysis buffer supplemented with 0.5 M imidazole. The purified protein was analyzed on 
SDS-PAGE gel (12 % acrylamide) B. E. coli expressing recombinant 6H-GFP-L-B1 
were suspended in lysis buffer (500 mM NaCl, 50 mM Tris at pH 8) and  lysed using 
French press (model number). The soluble lysate containing 6H-B1 was loaded onto a 
Ni-NTA agarose column. Impurities were removed by extensive washing with Lysis 
Buffer supplemented with 150 mM imidazole. 6H-B1 was eluted from the column with 
lysis buffer supplemented with 0.5 M imidazole. The purified protein was analyzed on 
SDS-PAGE gel (12 % acrylamide).  
 
 
 
3.2). TZM-bl cells were incubated with 2 µM GFP-L-B1 at 37°C and 5% CO2 for 
different amounts of time. After incubation, cells were treated with 0.04% Trypan Blue 
for two minutes to completely quench the signal from extracellular GFP (188), digested 
with 0.25% trypsin-EDTA for five minutes to completely remove the extracellular GFP 
and analyzed by flow cytometry (Figure 3.3A). GFP-L-B1 was found to rapidly and 
efficiently enter TZM-bl cells.  
 
Two major differences were noticed between cells that had taken up GFP-L-B1 
(+charge:MW ratio of 1.5) and those that had taken up the supercharged +36GFP  
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Figure 3.2. Cytotoxicity of GFP-L-B1 transduction. 293T, TZM and Huh 7.5 cells 
were seeded into 96 well plates at 2 x 104, 1.8 x 104 and 2 x 104 cells per well 
respectively. The next day, cells were washed with 100 µl OptiMEM before being 
treated with 0-5 µM GFP-L-B1, diluted in OptiMEM. 24 hours later, the relative cell 
viability was quantified using the CellTiter-Glo assay kit following the manufacturer’s 
protocol. 
 
 
 
(+charge:MW ratio of 1.3): (1) Fluorescence intensity. +36GFP-positive cells exhibited 
a much higher (up to 50-fold) fluorescence intensity on average than GFP-L-B1-positive 
cells (Figure 3.3A). (2) Intracellular distribution. Unlike +36GFP, which accumulated 
evenly in a large number of tiny, endosomal compartments, as gauged by the appearance 
of finely spotted cells, intracellular GFP-L-B1 was found to accumulate in much larger 
intracellular clusters in one subpopulation of cells while exhibiting an even diffuse 
distribution in another subpopulation (Figure 3.3B). Confocal microscopy confirmed that 
large GFP-L-B1 clusters formed in the paranuclear region of cells (Figure 3.3C).  
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Figure 3.3. B1 mediates cell transduction. A. Flow cytometry analysis of TZM-bl cells 
incubated with GFP-L-B1 (2 µM)or +36GFP (2 µM) at 37 °C for indicated times. B. 
Fluorescent microscope images of TZM-bl cells treated with 2 µM of GFP-L-B1 or 
+36GFP at 37 °C for 1 hour. Cells were washed with PBS containing 0.04% trypan blue 
prior to imaging. C. Confocal microscopic image of TZM cells treated with 2 µM GFP-
L-B1 at 37 °C for 1 hour. Cell nuclei were stained with DAPI (blue). 
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We also determined the ability of B1 to deliver covalently attached mCherry protein (32 
kDa) (189) into different cell types and evaluated B1 against other known cell-
penetrating  
 
 
 
Figure 3.4. B1 mediated mCherry transduction in selected cell lines. Jurkat, 293T, 
BSR, TZM, or Huh 7.5 cells were treated with the indicated mCherry-protein fusions for 
4 hours at 37 °C, prior to trypsin digestion and flow cytometry. Error bars represent the 
standard deviation of two independent experiments. 
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proteins/peptides. mCherry was attached to the N-terminus of B1, supercharged 
+36GFP, Tat and R10 (deca-arginine)  via a flexible linker (Table 3.1). As shown in 
Figure 3.4, 80-100% of all the target cells take up mCherry-L-B1 when exposed to a 
protein concentration as low as 1 µM. The potency of B1-mediated delivery of mCherry 
into cells was comparable to R10 and +36GFP and significantly higher than Tat.  
 
3.3.2 Abbreviated forms of B1 yield significantly weakened cell penetration 
We sought to determine whether B1’s cell penetration functionality could be traced to a 
specific region of the protein. B1 was segmented into three non-overlapping fragments 
that avoid the disruption of predicted structural motifs, named B1-F, B1-M, and B1-R 
(Figure 3.5A). As shown in the table at the bottom of Figure 3.5A, each segment 
comprises approximately one third of the mass of B1 and possesses a charge:MW ratio 
similar to the parental B1 (Figure 3.5B).  Each segment was fused to the C-terminus of 
eGFP via a flexible linker (Table 3.1) and the ability of TZM-bl cells to take up these 
constructs was measured. All three segments of B1 mediated cell penetration, with 
>80% of cells taking up the proteins at 5 µM exposure (Figure 3.5B). However, the cell 
penetration potency of these abbreviated forms of B1 is significantly lower than that of 
full-length B1. It is noteworthy that, compared to B1-R, B1-M possesses a lower 
charge:kDa ratio but exhibits a higher cell penetration potency.    
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3.3.3 B1-delivered proteins are able to access the cytosol and nucleus 
 Many cellular functions require proteins to be able to access the cytosol or nucleus. The 
punctate subcellular distribution of GFP-L-B1 (Figure 3.3C) raised the concern that B1 
may be trapped in subcellular compartments, without access to sites critical for cellular 
functions. To address this concern, we performed two major studies. The first study 
evaluated B1-mediated nuclear transport of protein cargo by measuring the ability of a 
B1-delivered recombinase to mediate DNA recombination. The second major study 
evaluated the ability of two types of nucleic acids – mRNA and DNA – to undergo 
processing by the cell’s transcription/translation machinery in the cytosol (mRNA) and 
nucleus (DNA).  
 
For the nuclear transport study, B1 was used to deliver covalently conjugated Cre 
recombinase into BSR.LNL.tdTomato cells (186). BSR.LNL.tdTomato cells contain two 
loxP recombination sites upstream of the reporter gene tdTomato, causing the gene to be 
silenced (189). Reporter gene expression is triggered by Cre-mediated DNA 
recombination (186). Cre fusions to B1 and R10 used in this study are depicted in Table 
3.1. A comparable extent of transfection was observed with +36GFP-L-Cre, Cre-L-B1 
and Cre-L-R10 based on fluorescence microscopic analysis (Figure 3.6A). We were 
unable to quantify the percentage of activated (tdTomato-expressing) cells in the 
+36GFP-L-Cre-exposed cell population via flow cytometry due to significant overlap in 
the fluorescence spectra of GFP and tdTomato (189, 190). Over 70% of cells were 
activated after exposure to 2.5 µM Cre-L-B1 or Cre-L-R10 (Figure 3.6B). As with  
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Figure 3.5. Transduction efficiency of truncated B1. A. B1 protein sequence 
including truncations resulting in B1-F (blue), B1-M (green), B1-R (yellow). Structural 
motifs were predicted using the GOR4 algorithm. B. Table showing the molecular 
weight and charge of B1 truncations. C, D. TZM cells were treated with the indicated 
GFP-protein fusions at 1, 2, 5 µM (C) or 1 µM (D) for 4 hours at 37 °C, prior to trypsin 
digestion and flow cytometry. The full length B1 mediates the most efficient GFP 
transduction. Error bars represent the standard deviation of two independent 
experiments. 
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+36GFP (186), chloroquine significantly enhanced Cre-induced recombination, 
particularly at low protein concentrations (Figure 3.6B). Chloroquine is a known 
inhibitor of lysosomal protein degradation (191) and likely extends the residence time of 
Cre fusion proteins in endosomes, allowing for increased escape.  
 
We next determined the ability of B1 to transport conjugated nucleic acids to cytosolic 
and nuclear sites accessible to the cell’s transcription/translation machinery, as assessed 
by the measurement of encoded reporter functions. To do this, we used two reporter 
constructs as payloads – the mRNA pIRF (3 kb) and the plasmid DNA pCMV5-Gluc 
(5.2 kbp). pIRF is a bicistronic mRNA containing a firefly luciferase (Fluc) gene 
expressed via cap-dependent translation and a Renilla luciferase (Rluc) gene expressed 
via the incorporated internal ribosome entry site (IRES) of hepatitis C virus (192). Only 
the Fluc reporter was quantified in this study. pCMV-Gluc encodes a Gaussia luciferase 
gene under the control of a CMV promoter (193). In this experiment and other studies 
described in this paper, GFP-L-B1 and not B1 was used as the CPP because of 
difficulties in obtaining large amounts of highly pure B1 protein. As seen in Figure 3.7A, 
GFP-L-B1 is able to bind pIRF mRNA, as gauged by the decreasing intensity of the 
mRNA band at increasing protein:mRNA molar ratios. At B1:pIRF molar ratios at and 
above 500, the mRNA was not able to migrate into the gel at all, indicating supershift of 
the mRNA. Similarly, B1 forms complexes with linearized plasmid DNA, although at a 
higher B1:nucleic acids ratio (Figure 3.7A). The higher molar ratio of B1 needed for 
DNA gel-shift likely derives from the larger molecular weight of the DNA.  
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Figure 3.6. B1 mediated cytosolic delivery of Cre. A. Brightfield and fluorescent 
images of BSR.LNL.td.Tomato reporter cells 24 hours after transduction with 2.5 µM 
Cre-L-B1, Cre-L-R10 and +36GFP-L-Cre. B.  Delivery of active CRE recombinase by 
B1 and R10 into BSR.LNL.td.Tomato reporter cells. Cells were treated with indicated 
concentrations of B1 or R10 in the presence or absence of 100 µM chloroquine for six 
hours at 37 °C. Chloroquine enhanced the delivery of active Cre into the cytosol at lower 
protein concentrations. Error bars represent the standard deviation of two independent 
experiments.  
  
 72 
 
Each pCMV5-Gluc DNA molecule has approximately 3 times the number of nucleotides 
as pIRF mRNA. It is also possible that B1 interacts more strongly with single-stranded 
RNA than double-stranded DNA. 
 
To determine the ability of B1 to transport nucleic acids to cytosolic sites accessible to 
the cell’s transcription/translation machinery, 1000:1 mixtures of either GFP-L-B1:pIRF 
or GFP-L-B1:pCMV5-Gluc were incubated with 293T cells for 6 hours. Our rationale 
for using a higher ratio of protein to nucleic acids than the minimum amount required for 
gel-shift was that each RNA/DNA molecule needs to form a complex with multiple B1 
proteins in order to be functionally delivered into cells (194). The activities of Fluc and 
Gluc deriving from intracellularly processed pIRF RNA (cytosol) and pCMV5-Gluc 
DNA (nucleus) were quantified several hours following exposure to cell penetration 
constructs. As a control, the same amounts of mRNA or DNA were transfected into 
293T cells using commercially available cationic lipid reagents according to the 
manufacturers’ protocols. As shown in Figure 3.7B, the efficiency of B1-mediated 
mRNA transfection is comparable to that obtained with the commercially available 
reagents TransMessenger and Lipofectamine 2000. Although +36GFP has been reported 
to support RNA interference by efficient delivery of siRNA (126), we found that 
exposure of 293T cells to +36GFP-conjugated pIRF reporter RNA did not yield a 
detectable Fluc reporter signal despite multiple attempts using different batches of 
purified proteins. The reason for this apparent discrepancy is unclear, but may derive 
from the much larger size of pIRF RNA (3 kb) relative to siRNA (22 bp). 
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Figure 3.7. B1 mediated cytosolic delivery of RNA, DNA and proteins. (A) Gel-shift 
assays of GFP-L-B1 conjugated DNA/RNA. pIRF RNA  (43 femto moles ) or linearized 
pCMV5 DNA (14.5 femto moles) were incubated with B1 protein at the indicated molar 
ratios in EMSA buffer for 10 minutes at room temperature analyzed on an agarose gel 
(0.8 %). (B) 293T cells were transfected with 1.6 nM of pIRF mRNA/linearized 
pCMV5-Gluc DNA using GFP-L-B1, +36GFP or the indicated commercial reagents 
according to manufacture protocol. TransMess: TransMessenger. Lipofec: 
Lipofectamine. Error bars represent the standard deviation from 2 independent 
experiments. 
 
 
 
Although +36GFP has been reported to support RNA interference by efficient delivery 
of siRNA (126), we found that exposure of 293T cells to +36GFP-conjugated pIRF 
reporter RNA did not yield a detectable Fluc reporter signal despite multiple attempts 
using different batches of purified proteins. The reason for this apparent discrepancy is 
unclear, but may derive from the much larger size of pIRF RNA (3 kb) relative to siRNA 
(22 bp). Another possible explanation is that pIRF RNA may interact with +36GFP in a 
way that inhibits its translation. DNA transfection mediated by GFP-L-B1 is 10-20-fold 
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weaker than that mediated by TransIT and Lipofectamine 2000, and ~100-fold stronger 
than that mediated by unmodified +36GFP (Figure 3.7C). It has previously been 
reported that the ability of free +36GFP to transport DNA into the nucleus is poor (126). 
However, +36GFP attached to a fusion peptide derived from hemagglutinin (126)can 
transfect DNA with similar efficiency as Lipofectamine (126). It is possible that an even 
higher DNA transfection efficiency can be achieved when B1 is fused to the same fusion 
peptide. 
 
3.3.4 B1 penetrates and traffics through cells via multiple endocytic pathways 
We attempted to elucidate the mechanism through which B1 penetrates cells. We first 
quantified cell penetration by GFP-L-B1 at different temperatures. As seen in Figure 
3.8A, although cell penetration by GFP-L-B1 is significantly weaker at lower 
temperatures all cells are able to take up GFP-L-B1 even at 4°C. This result indicates 
that B1 can penetrate cells in a temperature-independent manner.  
 
To determine the role of different cellular endocytic pathways in cell transduction by B1, 
we evaluated cellular uptake of GFP-L-B1 in the presence of selected inhibitors of 
macropinocytosis, clathrin-mediated endocytosis, mannan receptor-dependent 
phagocytosis, and caveolin-mediated endocytosis. No significant reduction in GFP-L-B1 
uptake was observed in the presence of any of the inhibitors in either 293T or TZM-b1 
cell line (Figure 3.8B), suggesting that any one of these pathways alone is not critical for 
GFP-L-B1 uptake by cells. In fact, GFP-L-B1 uptake by TZM-bl  cells appeared to be 
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somewhat enhanced by the macropinocytosis inhibitor amiloride (195) and clathrin-
mediated endocytosis inhibitor dynasore (196), and dramatically enhanced by 
chlorpromazine, another inhibitor of clathrin-mediated endocytosis (197) (Figure 3.8B, 
C). This result indicates that macropinocytosis and clathrin–mediated endocytosis may 
be “weak links” for cell transduction by B1 that obstruct B1–mediated protein entry 
through other, more energetically favorable pathways. 
 
The monitoring of green fluorescent cells following exposure of cells to GFP-L-B1 
provides a measure of cellular uptake of protein from the surroundings but does not 
provide information on its intracellular fate. 
 
We therefore sought to investigate the ability of cellular endocytic pathways to support 
the B1-mediated transport of an mRNA payload to sites accessible to the cell’s 
translation machinery. 293T cells were exposed to pIRF-mRNA-conjugated GFP-L-B1 
in the presence of endocytic inhibitors. In contrast to the data shown in Figure 3.8B, 
RNA transfection efficiency was significantly reduced by inhibitors of clathrin-mediated 
endocytosis (chlorpromazine, dynasore) and mannan receptor-dependent phagocytosis 
(100 µg/ml mannan (198)) (Figure 3.8D). 
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Figure 3.8. B1 enters/traffics through cells using multiple endocytic pathways.  The 
ability of these pathways to mediate cellular uptake does not correlate with the ability to 
support payload delivery to sites where bioactivity can be realized. A. Effect of 
temperature on cellular internalization of B1. TZM-bl cells were incubated with 2 µM 
GFP-L-B1 or 2 µM +36GFP at 4, 16, 22 or 37°C for one hour, washed with DPBS 
containing 0.04% Trypan Blue to quench extracellular GFP and analyzed by flow 
cytometry. B. Role of different endocytic pathways in cellular uptake of B1. TZM-bl or 
293T cells were pretreated with the endocytic inhibitors amiloride (5 mM) (195), 
chlorpromazine (55 µM) (197), dynasore (50 µM) (196), mannan (100 µg/ml) (198), 
nystatin (50 nM) (199) or cytochalasin B (4 µM) for one hour prior to the addition of 
GFP-L-B1 (2 µM). Part (D) indicates the endocytic pathways inhibited by these small 
molecules. One hour later, these cells were washed with DPBS containing 0.04% Trypan 
Blue and analyzed by flow cytometry. C. Fluorescence microscopic images of TZM-bl 
cells transfected with GFP-L-B1 in the presence of the indicated inhibitors. Data is 
representative of 4 independent experiments. D. Role of different endocytic pathways in 
supporting B1-mediated functional delivery of a RNA payload. 293T cells were 
pretreated with the indicated inhibitors for 1 hour prior to pIRF mRNA transfection 
using GFP-L-B1 or Lipofectamine 2000. The activity of Fluc deriving from translation 
of the delivered RNA was measured 6 hours post transfection. Error bars represent the 
standard deviation of two independent experiments. 
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Since cells are able to take up GFP-L-B1 even at 4°C and its transduction cannot be 
blocked by inhibiting known endocytic pathways, it is possible that B1 can penetrate 
cells in a temperature-independent mode. This observation raises the possibility that B1 
could permeabilize the cell membrane to facilitate uptake. To evaluate the permeability 
of B1, we treated TZM-bl cells with the membrane-impermeable dye propidium iodide 
in the presence of GFP-L-B1 (Figure 3.9) (200). Intracellular propidium iodide was not 
detected in the presence of B1, indicating that B1 does not permeabilize cell membranes. 
 
 
 
 
Figure 3.9. Cell membrane permeability of B1 treated cells. TZM cells were seeded 
into 24 well plates at 1.5 x 105 cells per well. The next day cells were washed once with 
OptiMEM before treatment with 5 µM GFP-L-B1 or 0.5% Tween for one hour at 37 °C 
in the presence of 3 ng/ml propidium iodide. After treatment cells were carefully washed 
once with cold DPBS followed by three washes with cold heparin solution (diluted to 50 
µg/ml in OptiMEM). After treatment cells were trypsinized, suspended, and cell 
permeability quantified based on propidium iodide fluorescence measured with flow 
cytometry. 
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Finally, we investigated the role of negatively charged cell-surface glycans on cellular 
uptake/processing of B1. 293T cells and TZM-bl cells were treated for 24 hours with 
sodium chlorate (80 mM), an inhibitor of glycan synthesis (201), prior to exposure to 
GFP-L-B1. B1-mediated cell uptake was reduced by sodium chlorate treatment (Figure 
3.10A). Similarly, GFP-L-B1-mediated RNA transfection was compromised in sodium 
chlorate-treated cells (Figure 3.10B). These results point to a role of cell-surface sulfated 
glycans in cell penetration by B1. 
 
3.4 Discussion 
This section describes a new cell penetrating polypeptide (CPP) – B1 – that derives from 
a frameshifted eGFP gene. B1 is able to rapidly and efficiently transport conjugated 
proteins (~30 kDa) and nucleic acids (~5 kbp DNA and 3 kb RNA) across cell 
membranes and to intracellular sites where bioactivity of the transported biomolecules 
can be realized. The kinetics of B1-mediated cell penetration is comparable to the 
published data for two other well-characterized CPPs – deca-arginine (R10) and Tat 
(125, 202).  
 
B1 effectively transports covalently conjugated proteins across the cell membrane, as 
evidenced by the fluorescence of cells exposed to B1-fused GFP. It is important to note 
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Figure 3.10. Probing the transduction mechanism of B1. A. Cell surface charge 
dependence of B1 mediated GFP transduction. TZM cells were treated with 80 mM 
sodium chlorate for 24 hours and then treated for one hour with 2 µM GFP-L-B1. 
Removing sulfated cell surface glycans did not consistently inhibit B1 mediated GFP 
transduction. B. Cell surface charge dependence on B1 mediated RNA transfection. 
293T cells were treated with 50 mM sodium chlorate for 24 hours. After treatment cells 
were transfected with 5 ng pIRF mRNA using GFP-L-B1 for 6 hours. Transfection 
efficiency was quantified 6 hours later and compared with untreated cells. Error bars 
show the standard deviation from two independent experiments. 
 
 
 
 
that this fluorescence analysis assesses cellular uptake of CPP-fused proteins but does 
not provide information on intracellular fate. It was found that, while mammalian cells 
readily take up B1-fused GFP, the mean fluorescence of the GFP-L-B1-exposed cells 
was significantly (~50-fold) lower than that of cells exposed to the supercharged 
+36GFP (186). Only a small proportion of GFP-L-B1-positive cells exhibit a 
fluorescence intensity on par with +36GFP-positive cells. The reduced intracellular 
fluorescence of GFP-L-B1 could be due to relatively quick transport from endosomes 
into lysosomes for degradation, preventing any increase in cellular fluorescence intensity 
after 30 minutes (Figure 3.3A). Another possibility is that GFP-L-B1 more readily 
escapes from endosomes relative to +36GFP, exposing it to degradation by cytosolic 
processes. 
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We demonstrated that B1 can efficiently penetrate many different mammalian cell lines, 
including both adherent and suspension cells. In all the tested cell lines, the percentage 
of mCherry-positive cells mediated by B1 delivery was comparable to +36GFP delivery, 
and was much higher than Tat delivery. Since cellular uptake was similar for both 
suspension cells (Jurkat) and adherent cells (HeLa, 293T, Huh-7.5), the amount of 
solution-exposed cell surface does not appear to be a limiting factor for cell penetration. 
Rather, given that the rate of uptake into cells is dependent primarily on association with 
the cell membrane, the overall turnover rate of the plasma membrane of a given cell line 
may more strongly influence protein uptake (203). As evidence of this hypothesis, it is 
noted that (1) BSR cells, which exhibit an unusually high metabolic rate (doubling time 
of ~12 h (186)), were observed to undergo the most potent cell penetration by B1, with 
essentially all cells being GFP-positive after exposure to 0.1 µM GFP-L-B1, and (2) the 
rate of uptake of B1 into TZM-bl cells is similar to published rates of membrane 
turnover (204). 
 
Despite being derived from a frameshifted gene, B1 is predicted to possess significant 
secondary structure (Figure 3.11). Efforts to assess the presence of secondary structure 
via circular dichroism (CD) analysis proved challenging, mainly due to difficulties in 
obtaining large amounts of highly pure B1, but preliminary data obtained from CD 
analysis appeared to indicate the presence of significant secondary structural motifs 
(Figure 3.12).  
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Figure 3.11. Secondary structure predictions of B1 amino acid sequence. Secondary 
structure predictions of the B1 protein were made using the GOR4 (A) (Garnier et al. 
1996) and Chou-Fasman (B) (Privelege et al. 1989) algorithms. A significant number of 
helical motifs were predicted by both algorithms (C). 
 
 
 
We segmented B1 into three non-overlapping fragments that avoid the disruption of 
predicted structural motifs (Figure 3.5A). Despite possessing similar charge:mass (kDa) 
ratios, these fragments were found to exhibit significantly weakened cell penetration 
relative to B1 (Figure 3.5B). This result implies that charge:mass ratio is not the only 
factor governing B1’s ability to penetrate and transport cargo across cellular barriers.  
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It is tempting to speculate that secondary, or even the tertiary, structure may play a role 
in B1’s cell penetration functionality. 
 
We demonstrated that B1 can deliver functional Cre recombinase to the nucleus, as 
gauged by reconstitution of expression of a silenced recombinant reporter gene. This 
result also implies that B1 can escape endosomes and access the cytosol. In our study, 
Cre was fused to the N-terminus of B1 and R10 via a flexible linker. Cre-mediated 
recombination is greatly enhanced by the presence of chloroquine, an inhibitor of 
lysosomal protein degradation (191).  
 
 
 
Figure 3.12. CD spectrum of 0.1 mg/ml B1 in ddH2O. Spectra were obtained from an 
AVIV 62DS spectropolarimeter by measuring every 1 nm between 190 and 250 nm with 
30 s averages.  
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The potency of B1-mediated delivery of Cre recombinase as gauged by nuclear 
recombination activity is significantly lower than that of B1-mediated delivery of 
mCherry as reported by cell fluorescence (compare chart for BSR cells in Figure 3.4 
with Figure 3.6B). This result indicates that the vast majority of covalently conjugated 
proteins delivered to cells by B1 are not accessible to the nucleus and perhaps also not 
accessible to the cytosol. These inaccessible proteins likely remain trapped in 
endosomes, consistent with the observation that GFP-L-B1 was found to accumulate in 
large intracellular patches (Figure 3.3B).  
 
Presumably, any cargo protein can be covalently attached to B1 for cell delivery.  Given 
that B1 is highly positively charged, a negatively charged cargo protein could potentially 
be non-covalently conjugated to B1 for cellular delivery. This strategy was successfully 
used by Waugh et al. to deliver negatively charged BOTOX into the skin of mice 
through conjugation with a Tat-polylysine fusion peptide (133). Alternatively, a 
disulfide bond could be inserted between the cargo protein and B1 through the 
introduction of a pair of cysteine substitutions in both proteins. Upon delivery to the 
reducing environment of the cytosol, the disulfide linkage is likely to break. Wiyagi et 
al. used this approach to deliver a δPKC inhibitor peptide into mice through using Tat as 
the CPP (134).  
 
To determine the role of different cellular endocytic pathways in cell penetration by B1, 
we evaluated cellular uptake of GFP-L-B1 in the presence of selected inhibitors of 
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macropinocytosis, clathrin-mediated endocytosis, mannan receptor-dependent 
phagocytosis, and caveolin-mediated endocytosis. None of these inhibitors blocked 
uptake of GFP-L-B1, suggesting that any one of these cellular pathways alone is not 
critical for cellular entry of B1. In fact, B1 uptake by TZM-bl cells is enhanced by 
inhibitors of macropinocytosis and clathrin-mediated endocytosis (Figure 3.8B, C). This 
result indicates that macropinocytosis and clathrin-mediated endocytosis may be “weak 
links” for cell penetration by B1 that obstruct B1-mediated protein entry through other, 
more energetically favorable pathways. In contrast, nystatin, an inhibitor of caveolin–
mediated endocytosis, was found to enhance the delivery of mRNA pointing to a 
possible inhibitory role of caveolin–mediated endocytosis in mRNA cargo delivery. 
 
The discrepancy in the roles of endocytic pathways in cellular uptake versus successful 
processing of an mRNA cargo underscores the lack of correlation between B1’s cell-
transduction ability and its access to cellular sites conducive to cargo bioactivity. 
Clathrin-mediated endocytosis is an example of a pathway that is dispensable for cellular 
uptake of B1 (Figure 3.8B) but critical for providing cytosolic access to B1–conjugated 
cargo (Figure 3.8D).  In this example, it is possible that blockage of clathrin–mediated 
endocytosis forces B1 to enter cells through other endocytic pathways whose endosomal 
compartments are less permissive to cytosolic access (131).  
 
An endocytic pathway is presumed since fluorescence imaging indicates that the GFP–
fused protein appears to be agglomerated in punctate regions presumed to be endosomes 
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(Figure 3.3B, C). Any form of direct membrane translocation is not expected, since B1 is 
composed of mainly hydrophilic residues, and since the cell membrane remains intact 
during transduction (Figure 3.9). Such pathways would presumably be responsible for 
the GFP transduction observed at 4 °C, and would as such possess a relatively limited 
energy dependence. Since the known mechanisms of cellular transport require 
considerable amounts of energy and cellular resources, such a pathway must therefore 
use a currently undescribed mechanism. It is likely that other cell transducing proteins 
also make use of this mechanism. Elucidating the details of this mechanism, however, 
will prove a challenge. This is because B1, and other cell transducing proteins, are 
capable of delivering their cargo via multiple mechanisms (205, 206).  
 
Finally, we explored the role of negatively charged cell-surface glycans in cellular 
uptake/processing of B1 based on our hypothesis that cell-surface ionic interactions play 
a role in B1’s ability to associate with and enter cells. We found that lowering the cell-
surface content of sulfated glycans via sodium chlorate treatment does indeed retard the 
ability of GFP-L-B1 to penetrate and deliver functional cargo into cells. Previously, 
Cronican et al. observed that highly positively charged proteins can efficiently penetrate 
mammalian cells and predicted that proteins with a +charge:MW ratio greater than 0.75 
represent candidate CPPs (126, 127). B1 possesses a +charge:MW ratio of 1.5, further 
supporting a role of ionic interactions in at least partially mediating its cell penetration 
functionality. 
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In conclusion we identified a new cell-penetrating protein, B1, which is able to potently 
deliver conjugated biomolecular cargo to several mammalian cell lines. Most 
importantly, we show that B1 not only mediates cellular uptake, but effectively 
transports cargo to intracellular sites of biological relevance. B1 appears to utilize cell-
surface glycans for cellular entry and penetrates cells and transports its cargo via 
multiple competing cellular endocytic pathways. Interestingly, we found that the 
contribution of specific endocytic pathways to cellular entry versus functional cargo 
delivery by B1 can be significantly different. B1 provides a new tool for intracellular 
delivery of biomolecules. Additionally, insights garnered from these studies could aid in 
the design of more effective vehicles for the cellular delivery of therapeutic payloads. 
 
3.5 Methods 
3.5.1 Cellular uptake determination of fluorescent protein-fused CPPs 
On the day prior to CPP exposure, the following cells were seeded in 24-well plates at 
the indicated densities: 293T cells (2 x 105 cells/well), Huh-7.5 and TZM cells (1.9 x 105 
cells/well), BSR cells (1 x 105 cells/well).  These seeding densities were chosen such that 
the cells reach ~70% confluency the following day. On the day of CPP exposure, Jurkat 
cells were transferred to V-bottom 96-well plates at 1 x 105 cells/well. All cells were 
washed once with OptiMEM to remove residual serum. Protein solutions were diluted in 
cold OptiMEM to the desired concentrations and equilibrated to room temperature 
before being added to cells. Cells were incubated at 37°C/5% CO2 unless otherwise 
indicated. After incubation, these cells were washed once with cold DPBS.  
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For uptake determination of GFP-L-B1 or +36 GFP, cells were incubated with 0.04% 
Trypan Blue (in DPBS) for 2 minutes at room temperature to quench the fluorescence of 
extracellular GFP (188), washed again with cold DPBS and then imaged using a Zeiss 
Axiovert 200M fluorescent microscope (Carl Zeiss Microscopy, NY). For confocal 
microscopy, TZM cells (seeded on a glass chamber slide) that had been exposed to 2 µM 
GFP-L-B1 were incubated with 300 nM DAPI solution (Invitrogen, NY) for 5 minutes at 
room temperature and imaged using a Zeiss 510 Meta NLO Mulitphoton microscope 
(Carl Zeiss Microscopy). For flow cytometric analysis, cells that had been exposed to 
CPPs were incubated with 0.25% trypsin-EDTA at room temperature for 5 minutes and 
resuspended in complete growth medium (DMEM supplemented with 10% FBS and 1X 
NEAA) and analyzed on a BD FACScan flow cytometer (BD Biosciences) gated for 
GFP fluorescence (excitation/emission 488/530). At least 1 x 104 cells were analyzed for 
each sample. 
 
For cellular uptake analysis of CPPs containing mCherry-fusion proteins, CPP-exposed 
cells were detached by incubation with 0.25% trypsin-EDTA at room temperature for 
five minutes, resuspended in complete growth medium and then analyzed by flow 
cytometry (excitation/emission 488/650). At least 1 x 104 cells were analyzed for each 
sample. 
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3.5.2 Cre recombinase delivery 
BSR.LNL.tdTomato reporter cells were seeded in 24-well plates at 5 x 104 cells per well. 
The following day, the cells were washed once with OptiMEM to remove residual 
serum, exposed to Cre-fused CPPs in the presence or absence of 100 µM chloroquine 
and incubated at 37°C/5% CO2 for 6 hours. Following CPP exposure, cells were washed 
once with OptiMEM to remove excess proteins, the supernatants were replaced with 
fresh, complete growth medium, and the cells were incubated at 37°C/5% CO2 for 
another 24 hours followed by fluorescence microscopic analysis (Zeiss Axiovert 200M) 
to quantify Cre delivery. After imaging, cells were trypsinized, resuspended in complete 
growth medium and then analyzed by flow cytometry (excitation/emission 488/650). 
Cells were gated for at least 1 x 104 live cells in each sample.  
 
3.5.3 Quantification of luciferase activity deriving from DNA/RNA delivery 
293T cells were seeded in 96-well plates at 4 x 104 cells per well. The following day, 
10X-concentrated protein samples were prepared in OptiMEM. Linearized pCMV5-Gluc 
DNA (46 ng/µL) and pIRF mRNA (10 ng/µL) were prepared in OptiMEM. 10 µL of 
10X protein samples were mixed with 10 µl of the nucleic acids and the mixtures were 
incubated at room temperature for 10 minutes to allow protein/nucleic acids association. 
In the meantime, the cells were washed twice with OptiMEM to remove residual serum 
and incubated in 40 µL OptiMEM. 10 µL of the protein/nucleic acids mixtures were then 
added to cells followed by incubation at 37°C/5% CO2 for 6 hours. The amount of RNA 
and DNA in individual wells was 50 ng (50.5 fmol) and 230 ng (67 fmol), respectively. 
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For control experiments utilizing commercial reagents for nucleic acids delivery, 
linearized pCMV5-Gluc (230 ng in 10 µL) was mixed with 0.8 µL Lipofectamine 2000 
or TransIT reagent and pIRF mRNA (50 ng in 10 µL) was mixed with 0.4 µL 
Lipofectamine 2000 or TransMessenger reagent. The mixtures were incubated at room 
temperature for 20 minutes, diluted in 40 µL OptiMEM and added to 293T cells. 6 hours 
later, the cells were washed and the supernatants were replaced with the complete 
growth medium. DNA transfection was quantified by measuring the Gaussia luciferase 
(Gluc) activity in supernatants 24 hours post medium change using the Biolux Gaussia 
Luciferase Assay Kit (New England Biolabs). RNA transfection was quantified by 
measuring the intracellular firefly luciferase (Fluc) levels measured 6 hours post medium 
change using the Luciferase Assay System (Promega). 
 
3.5.4 Chemicals, bacterial strains and cell lines  
BSR.LNL.tdTomato reporter cells were a gift from Prof. David Liu (Harvard 
University). 293T cells were purchased from Invitrogen. TZM–bl cells were obtained 
from Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc. through the NIH AIDS 
Reagent Program, Division of AIDS, NIAID. Jurkat cells were obtained from Prof. Paul 
Lindahl (Texas A&M University). Huh–7.5 cells were obtained from Prof. Charles Rice 
(Rockefeller University). 
All adherent cell lines were cultured in complete growth medium (Dulbecco’s Modified 
Eagle Medium (DMEM) containing 4500 mg/L glucose, 4.0 mM L–Glutamine, and 110 
mg/L sodium pyruvate (Thermo Scientific HyClone) supplemented with 10 % fetal 
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bovine serum (Atlanta Biologicals) and 1X non–essential amino acids (Thermo 
Scientific HyClone)). Jurkat cells were cultured in Roswell Park Memorial Institute 
Medium (RPMI) 1640 (Lonza) supplemented with 10% fetal bovine serum. 
Escherichia coli strains DH5α (Invitrogen) and BL21 (DE3) (New England Biolabs) 
were used for recombinant DNA cloning and recombinant protein expression, 
respectively. 
 
Amiloride and dynasore were purchased from Enzo Life Sciences. Chlorpromazine, 
mannan and cytochalasin B were obtained from Sigma–Aldrich. Nystatin was purchased 
from Amresco. CellTiter–Glo Luminescent Cell Viability Assay Kit and Luciferase 
Assay System were purchased from Promega. Biolux Gaussia Luciferase Assay Kit was 
purchased from New England Biolabs. Dulbecco's Phosphate–Buffered Saline (DPBS) 
was purchased from Thermo Scientific HyClone. OptiMEM and Lipofectamine 2000 
were purchased from Invitrogen. 0.4% Trypan Blue solution was purchased from Lonza. 
Luria–Bertani (LB) broth, Mirus TransIT LT1 transfection reagent and ampicillin were 
obtained from Thermo Fisher Scientific. Isopropyl–β–D–thiogalactopyranoside (IPTG), 
0.25% trypsin–EDTA and imidazole were from VWR International. TransMessenger 
transfection reagent was purchased from Qiagen. 
 
3.5.5 Protein purification 
BL21 (DE3) cells were transformed with the expression plasmid and plated on a Luria–
Bertani (LB) agar plate containing 100 µg/mL ampicillin. The next day, a single colony 
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was picked and cultured at 37°C with shaking at 250 rpm. At OD600 ~0.6, the cells were 
cooled to 18°C and isopropyl β–D–1–thiogalactopyranoside (IPTG, 0.5 mM) was added 
to the culture to induce protein expression. After overnight expression (~18 hours) at 
18°C, cells were harvested by centrifugation at 6000 x g and 4°C for 20 minutes and 
pellets were stored at –80 °C until use.  
 
For recombinant protein purification, cell pellets were resuspended in lysis buffer (500 
mM NaCl, 50 mM Tris, pH 8, 10 mL per 1 g wet cell pellet), and disrupted by sonication 
on ice (QSonica Misonix 200 (Qsonica), 1 second pulse 6 second pause for 3 minutes 10 
amp). Whole cell lysate was clarified by centrifugation at 20,000 x g for 20 minutes at 
4°C. Soluble cell lysates were loaded onto 5 mL Ni–NTA agarose beads (Qiagen). For 
constructs expressing B1 or +36GFP, the loaded resin was washed with lysis buffer 
supplemented with 150 mM imidazole and the product was eluted in lysis buffer 
supplemented 500 mM imidazole. For all other constructs the loaded resin was washed 
with lysis buffer supplemented with 50 mM imidazole and the product was eluted in 
lysis buffer supplemented 150 mM imidazole. Purified protein samples were dialyzed 
overnight at 4°C into Buffer A (2 M NaCl, 2.7 mM KCl, 10 mM Na2HPO4.2H2O, 2 mM 
KH2PO4, pH 7.4). The proteins +36GFP and Cre-L-B1 were further purified by cation 
exchange chromatography using a GE HiTrap SP HP column (GE Biosciences, PA). 
Dialyzed proteins were diluted 1:5 into PBS to reduce the salt concentration and then 
loaded onto the SP column. The column was washed with Buffer B (0.5 M NaCl, 2.7 
mM KCl, 10 mM Na2HPO4.2H2O, 2 mM KH2PO4, pH 7.4) and the target protein was 
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eluted in Buffer A. Purified proteins were concentrated via ultracentrifugation through 
an Amicon 10 kDa MWCO centrifugal column (EMD Millipore). The final protein 
concentrations were determined using a Pierce Coomassie Plus Protein Assay Kit 
(Thermo Fisher Scientific).  
 
Typically the purification yield of GFP-L-B1 using this approach is ~15 mg per liter of 
E. coli culture. It is worth noting that although a high concentration of NaCl (0.5M) is 
needed to maintain B1-fusion protein soluble at the stock concentration (i.e. when B1 is 
concentrated at ~100 µM), such high concentrations of NaCl were not needed during cell 
transduction. The highest final salt concentration used in these experiments was ~230 
mM (Figure 3.4, 5 µM GFP-L-B1). Minimal cellular toxicity was observed under this 
condition (Figure 3.2). 
 
3.5.6 Gel shift of GFP-L-B1-conjugated DNA/RNA 
pCMV5–Gluc DNA was linearized by digestion with XbaI. pIRF mRNA was 
transcribed and capped from the XhoI digested plasmid DNA template using the 
Ampliscribe T7 High Yield Transcription Kit (Epicentre) with the addition of the 
monomethlyated RNA cap analog (Cell Script) following the manufacturer’s protocol. 
Linearized pCMV5–Gluc plasmid DNA (14.5 femtomoles or 50 ng) or pIRF mRNA (86 
femtomoles or 80 ng) were mixed with GFP–L–B1 at the following protein:DNA/RNA 
molar ratios: 0:1, 10:1, 50:1, 100:1, 500:1, 1000:1 in EMSA buffer (4% glycerol, 1 mM 
MgCl2, 0.5 mM EDTA, 0.5 mM DTT, 50 mM NaCl, 10 mM Tris–HCl, pH 7.4). The 
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mixtures were incubated at room temperature for 10 minutes to allow protein–
DNA/RNA association. Formation of protein/nucleic acids complexes was confirmed by 
analysis on a 0.8% agarose gels (100 V for 40 minutes for DNA and 120 V for 15 
minutes for RNA). The ethidium bromide–stained gel was then visualized under UV 
exposure. 
 
3.5.7 Interrogation of role of cellular endocytic pathways 
293T and TZM–bl cells were seeded in 24–well plates at 1.5 x 105 cells per well. The 
following day, cells were washed with 500 µl OptiMEM to remove residual serum and 
incubated in 200 µL OptiMEM containing endocytic inhibitors for 1 hour at 37°C/5% 
CO2. 20 µM GFP–L–B1 (in 20 µL) or mixtures of GFP–L–B1 (8 µM) and pIRF mRNA 
(5 ng (5 fmol))were added to the cells in the continued presence of the inhibitors and 
incubation at 37°C/5% CO2 for one hour. For analysis of cellular uptake/functional cargo 
delivery, cells were washed once with cold DPBS, incubated with DPBS containing 
0.04% Trypan Blue at room temperature for 2 minutes to quench the fluorescence of 
extracellular GFP (188), and analyzed via fluorescence microscopy (Zeiss Axiovert 
200M) or flow cytometry (excitation/emission 488/530). At least 1 x 104 cells were 
analyzed for each sample. Firefly luciferase (Fluc) activity deriving from pIRF mRNA 
delivery was quantified 6 hours post exposure to GFP–L–B1/mRNA complex using the 
Luciferase Assay System (Promega). 
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3.5.8 Interrogation of role of cell–surface glycans 
For GFP–L–B1 delivery, 293T and TZM–bl cells were seeded in 24–well plates at 7.5 x 
104 and 1.5 x 105 cells/well, respectively. For the assessment of functional mRNA 
delivery, 293T cells were seeded in 96–well plates at 1.5 x 104 cells per well. The 
following day, cells were washed with OptiMEM to remove residual serum and 
incubated with either 2 µM GFP–L–B1 for one hour or mixtures of 1.6 µM GFP–L–B1 
and 5 ng (5 fmol) pIRF mRNA for 6 hours. For assessment of GFP–L–B1 uptake, cells 
were washed once with cold DPBS, incubated in DPBS containing 0.04% Trypan Blue 
at room temperature for 2 minutes, and analyzed via fluorescence microscopy (Zeiss 
Axiovert 200M) or flow cytometry (excitation/emission 488/530). At least 1 x 104 cells 
were analyzed for each sample. Functional delivery of pIRF mRNA was determined by 
measuring intracellular Fluc activity 6 hours post transfection using the Luciferase Assay 
System. 
 
3.5.9 Cloning 
The codon–optimized B1 gene was synthesized by Genscript (Piscataway). All 
constructs were expressed using the pET15b vector, which contains an N–terminal 
6xHistidine tag. mCherry was amplified from pET–+36GFP–L–mCherry (a gift from 
Prof. David Liu, Harvard University). Cre was amplified from pET–+36GFP–L–Cre 
(gift from Prof. David Liu). DNA fragments encoding linkers were synthesized by 
Integrated DNA Technologies and inserted into the appropriate vectors via overlap 
extension PCR.  
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3.5.10 Sequences of Proteins used in this section 
(1) B1 
MGSSHHHHHHSSGLVPRGSHMWFKREQGRGAVHRGGAHPGRAGRRRKRPQV
QRVRRGRGRCHLRQADPEVHLHHRQAARALAHPRDHPDLRRAVLQPLPRPHEA
ARLLQVRHARRLRPGAHHLLQGRRQLQDPRRGEVRGRHPGEPHRAEGHRLQG
GRQHPGAQAGVQLQQPQRLYHGRQAEERHQGELQDPPQHRGRQRAAHRPLPA
EHPHRRRPRAAARQPLPEHPVRPEQRPQREARSHGPAGVRDRRRDHSRHGRGL
N 
 
(2) GFP-L-B1 
MGSSHHHHHHSSGLVPRGSHMVSKGEELFTGVVPILVELDGDVNGHKFSVSGE
GEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKS
AMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHK
LEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVL
LPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELEACGGGGSGGG
GSASWFKREQGRGAVHRGGAHPGRAGRRRKRPQVQRVRRGRGRCHLRQADPE
VHLHHRQAARALAHPRDHPDLRRAVLQPLPRPHEAARLLQVRHARRLRPGAHH
LLQGRRQLQDPRRGEVRGRHPGEPHRAEGHRLQGGRQHPGAQAGVQLQQPQR
LYHGRQAEERHQGELQDPPQHRGRQRAAHRPLPAEHPHRRRPRAAARQPLPEH
PVRPEQRPQREARSHGPAGVRDRRRDHSRHGRGLN 
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(3) GFP-L-B1-F 
MGSSHHHHHHSSGLVPRGSHMVSKGEELFTGVVPILVELDGDVNGHKFSVSGE
GEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKS
AMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHK
LEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVL
LPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELEACGGGGSGGG
GSASWFKREQGRGAVHRGGAHPGRAGRRRKRPQVQRVRRGRGRCHLRQADPE
VHLHHRQAARALAHPRDHPDLRRAVLQPLPRPLEDPAANKARKEAELAAATAE
Q 
 
(4) GFP-L-B1-M 
MGSSHHHHHHSSGLVPRGSHMVSKGEELFTGVVPILVELDGDVNGHKFSVSGE
GEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKS
AMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHK
LEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVL
LPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELEACGGGGSGGG
GSASQPLPRPHEAARLLQVRHARRLRPGAHHLLQGRRQLQDPRRGEVRGRHPG
EPHRAEGHRLQGGRQHPGAQAGVQLQQPQRLYHGRQAEERHQGELQDPP 
 
(5) GFP-L-B1-R  
MGSSHHHHHHSSGLVPRGSHMVSKGEELFTGVVPILVELDGDVNGHKFSVSGE
GEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKS
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AMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHK
LEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVL
LPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELEACGGGGSGGG
GSASELQDPPQHRGRQRAAHRPLPAEHPHRRRPRAAARQPLPEHPVRPEQRPQR
EARSHGPAGVRDRRRDHSRHGRGLN 
 
(6) mCherry-L-B1  
MGSSHHHHHHSSGLVPRGSHMVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFE
IEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDY
LKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPV
MQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKK 
PVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKTGGSGGSG
GSGGSGGSGGSGGSGGSSASWFKREQGRGAVHRGGAHPGRAGRRRKRPQVQR
VRRGRGRCHLRQADPEVHLHHRQAARALAHPRDHPDLRRAVLQPLPRPHEAAR
LLQVRHARRLRPGAHHLLQGRRQLQDPRRGEVRGRHPGEPHRAEGHRLQGGR
QHPGAQAGVQLQQPQRLYHGRQAEERHQGELQDPPQHRGRQRAAHRPLPAEH
PHRRRPRAAARQPLPEHPVRPEQRPQREA 
RSHGPAGVRDRRRDHSRHGRGLN 
 
(7) mCherry-L-Arg10 
MGSSHHHHHHSSGLVPRGSHMVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFE
IEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDY
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LKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPV
MQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKK 
PVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKTGGSGGSG
GSGGSGGSGGSGGSGGSSASRRRRRRRRRR 
 
(8) mCherry-L-Tat  
MGSSHHHHHHSSGLVPRGSHMVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFE
IEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDY
LKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPV
MQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKK 
PVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKTGGSGGSG
GSGGSGGSGGSGGSGGSSASGRKKRRQRRR 
 
(9) Cre-L-B1  
MGSSHHHHHHSSGLVPRGSHMASNLLTVHQNLPALPVDATSDEVRKNLMDMF
RDRQAFSEHTWKMLLSVCRSWAAWCKLNNRKWFPAEPEDVRDYLLYLQARG
LAVKTIQQHLGQLNMLHRRSGLPRPSDSNAVSLVMRRIRKENVDAGERAKQAL
AFERTDFDQVRSLMENSDRCQDIRNLAFLGIAYNTLLRIAEIARIRVKDISRTD 
GGRMLIHIGRTKTLVSTAGVEKALSLGVTKLVERWISVSGVADDPNNYLFCRVR
KNGVAAPSATSQLSTRALEGIFEATHRLIYGAKDDSGQRYLAWSGHSARVGAA
RDMARAGVSIPEIMQAGGWTNVNIVMNYIRNLDSETGAMVRLLEDGDGAPSGG
GGSGGGGSASWFKREQGRGAVHRGGAHPGRAGRRRKRPQVQRVRRGRGRC 
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HLRQADPEVHLHHRQAARALAHPRDHPDLRRAVLQPLPRPHEAARLLQVRHAR
RLRPGAHHLLQGRRQLQDPRRGEVRGRHPGEPHRAEGHRLQGGRQHPGAQAG
VQLQQPQRLYHGRQAEERHQGELQDPPQHRGRQRAAHRPLPAEHPHRRRPRAA
ARQPLPEHPVRPEQRPQREARSHGPAGVRDRRRDHSRHGRGLN 
 
(10) Cre-L-Arg10  
MGSSHHHHHHSSGLVPRGSHMASNLLTVHQNLPALPVDATSDEVRKNLMDMF
RDRQAFSEHTWKMLLSVCRSWAAWCKLNNRKWFPAEPEDVRDYLLYLQARG
LAVKTIQQHLGQLNMLHRRSGLPRPSDSNAVSLVMRRIRKENVDAGERAKQAL
AFERTDFDQVRSLMENSDRCQDIRNLAFLGIAYNTLLRIAEIARIRVKDISRTD 
GGRMLIHIGRTKTLVSTAGVEKALSLGVTKLVERWISVSGVADDPNNYLFCRVR
KNGVAAPSATSQLSTRALEGIFEATHRLIYGAKDDSGQRYLAWSGHSARVGAA
RDMARAGVSIPEIMQAGGWTNVNIVMNYIRNLDSETGAMVRLLEDGDGAPSGG
GGSGGGGSASRRRRRRRRRR 
 
(11) +36GFP  
MGHHHHHHGGASKGERLFRGKVPILVELKGDVNGHKFSVRGKGKGDATRGKL
TLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPKHMKRHDFFKSAMPKGYVQE
RTISFKKDGKYKTRAEVKFEGRTLVNRIKLKGRDFKEKGNILGHKLRYNFNSHK
VYITADKRKNGIKAKFKIRHNVKDGSVQLADHYQQNTPIGRGPVLLPRNHYLST
RSKLSKDPKEKRDHMVLLEFVTAAGIKHGRDERYK 
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(12) +36GFP-L-mCherry  
MASKGERLFRGKVPILVELKGDVNGHKFSVRGKGKGDATRGKLTLKFICTTGK
LPVPWPTLVTTLTYGVQCFSRYPKHMKRHDFFKSAMPKGYVQERTISFKKDGK
YKTRAEVKFEGRTLVNRIKLKGRDFKEKGNILGHKLRYNFNSHKVYITADKRK
NGIKAKFKIRHNVKDGSVQLADHYQQNTPIGRGPVLLPRNHYLSTRSKLSKDPK
EKRDHMVLLEFVTAAGIKHGRDERYKGGSGGSGGSGGSGGSGGSGGSGGSGGS
VSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTK
GGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMNFEDGG
VVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDG
ALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDY
TIVEQYERAEGRHSTGGMDELYKLEHHHHHH 
 
(13) +36GFP-L-Cre  
MASKGERLFRGKVPILVELKGDVNGHKFSVRGKGKGDATRGKLTLKFICTTGK
LPVPWPTLVTTLTYGVQCFSRYPKHMKRHDFFKSAMPKGYVQERTISFKKDGK
YKTRAEVKFEGRTLVNRIKLKGRDFKEKGNILGHKLRYNFNSHKVYITADKRK
NGIKAKFKIRHNVKDGSVQLADHYQQNTPIGRGPVLLPRNHYLSTRSKLSKDPK
EKRDHMVLLEFVTAAGIKHGRDERYKGGSGGSGGSGGSGGSGGSGGSGGSGGS
ASNLLTVHQNLPALPVDATSDEVRKNLMDMFRDRQAFSEHTWKMLLSVCRSW
AAWCKLNNRKWFPAEPEDVRDYLLYLQARGLAVKTIQQHLGQLNMLHRRSGL
PRPSDSNAVSLVMRRIRKENVDAGERAKQALAFERTDFDQVRSLMENSDRCQDI
RNLAFLGIAYNTLLRIAEIARIRVKDISRTDGGRMLIHIGRTKTLVSTAGVEKALS
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LGVTKLVERWISVSGVADDPNNYLFCRVRKNGVAAPSATSQLSTRALEGIFEAT
HRLIYGAKDDSGQRYLAWSGHSARVGAARDMARAGVSIPEIMQAGGWTNVNI
VMNYIRNLDSETGAMVRLLEDGDGGSHHHHHH 
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4. TACHYKININ RECEPTOR 1 & 3 ANTAGONISTS INHIBIT HCV INFECTION  
 
4.1 Overview 
Tachykinin receptors (TACR) are G-protein coupled receptors that are ubiquitously 
found in humans. Tachykinin receptors are usually stimulated by small signaling 
peptides, called tachykinins. 
 
Due to their expression in a wide range of tissues, tachykinin receptors mediate a wide 
range of functions in vivo. TACR antagonists have long been developed for a wide range 
of clinical indications, including HIV infection. During a screening carried out in our 
lab, we identified a TACR3 inhibitor SB 222200 that had significant anti-HCV activity. 
In this section, we show that both TACR1 and TACR3 receptors are expressed in the 
HCV-permissive Huh 7.5 cell line. We also show that both TACR1 and TACR3 
inhibitors significantly inhibit HCV infection. These results point to the potential for 
TACR1 antagonists in treating patients infected with both HCV and HIV.  
 
4.2 Introduction 
Tachykinins (also known as neurokinins) are peptides characterized by a common C-
terminal sequence that binds to and activates a cell surface-localized tachykinin receptor 
(62). The three main tachykinin peptides (Substance P (SP), Neurokinin A (NKA) and 
Neurokinin B (NKB)) are distributed throughout the body, but are usually predominantly 
found in the CNS(63, 64). The tachykinin receptor is a G-protein coupled receptor 
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containing seven trans-membrane helices(65). Three different tachykinin receptors 
(TACR) have been identified – tachykinin receptors 1, 2 and 3 (TACR1, TACR2 and 
TACR3) – and although each receptor can be activated by any of the three main 
tachykinin peptides, SP, NKA, and NKB have higher affinities for TACR1, TACR2 and 
TACR3 respectively (66). This apparent lack of specificity is likely due to a high 
homology at the ligand-binding site among these receptors(67).  
 
The binding of an agonist to the receptor initiates a cascade of intracellular signaling 
events leading to the activation of phospholipase C (PLC), inositol triphosphate (IP3) and 
diaglycerol (DAG)(68). These two molecules can then act to increase the calcium 
concentration in the cytoplasm from two different sources. IP3 can bind to and activate 
the IP3 receptor on the ER membrane (69). This results in the release of calcium from the 
ER to the cytoplasm. DAG can activate protein kinase C (PKC) which opens L-type 
calcium channels in the cell membrane, enabling calcium influx from the extracellular 
environment(70). Perhaps due to this non-specific signal cascade, tachykinins can be 
responsible for a wide range of effects. This, combined with the relatively large tissue 
distribution, leads to tachykinins being involved in a number of functions including: 
neuronal survival and regeneration; gastric mobility; regulation of respiratory 
mechanisms; and the expression of pro-inflammatory cytokines (71-73). As such TACR 
antagonists, have been tested for a wide range of indications in clinical trials. TACR1 
antagonist aprepitant has been tested as an antiemetic, an antidepressant, a CYP34A 
inhibitor, and to treat urge urinary incontinence (74-77). TACR1 antagonist CP 99994 
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has been tested as a post-operative analgesic (78). TACR2 antagonists nepadutant and 
saredutant have been tested for the treatment of irritable bowel syndrome, and the 
inhibition of NKA induced bronchoconstriction (79, 80). Finally, TACR3 antagonist 
osanetant has been tested as an anti-psychotic (81). 
 
In addition to their roles in native body functions, tachykinin ligands and receptors have 
been implicated in the infection of some viruses (82, 83). For HIV it was observed that 
HIV-infected individuals had significantly increased levels of SP (84). It was also shown 
that SP binding lead to increased HIV replication in infected cells, including the 
activation of latently infected immune cells (85, 86). And finally that TACR1 
antagonists inhibit HIV infection in vitro (83, 87, 88). Aprepitant, a TACR1 antagonist, 
was used in a clinical study for HIV treatment, but the study failed due to the inability to 
reach effective physiological concentrations at safe doses (89). The first implied role of 
tachykinins and HCV occurred when a TACR3 tachykinin receptor antagonist, SB 
222200, appeared as a hit in a screen for anti-HCV small molecules carried out in our lab 
(90). Tachykinin receptors are also known to be expressed in the liver, albeit at low 
levels (207). Put together, those two initial observations point to a likely involvement of 
one or more tachykinin receptors in the HCV life cycle. However, due to the relative 
lack of specificity of the antagonists used, and the number of enzymes and processes 
potentially activated by the receptor, the role of the tachykinin receptor in the HCV life 
cycle is not immediately apparent. Characterization of the anti-HCV activity of SB 
222200, a tachykinin receptor antagonist, could therefore shed light on previously 
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unknown or poorly understood virus-host interactions and open the door to a new class 
of anti-HCV drugs. Here we show that both the TACR1 and TACR3 receptors are 
expressed in the HCV-permissive Huh 7.5 cell line (98). In addition, we demonstrate 
that antagonists of both receptors inhibit HCV infection.  
 
4.3 Results 
4.3.1 TACR1 and TACR3 antagonists inhibit HCV infection  
TACR1 and TACR3 receptors are expected to be expressed in the liver, and we 
previously demonstrated the ability of TACR3 antagonist SB 222200 to inhibit HCV 
infection. We first tested the anti-HCV capability of an additional TACR3 antagonist, 
and two selected TACR1 antagonist (Figure 4.1). As shown in Figure 4.2, all tested 
antagonists showed significant anti-HCV activity at low micromolar concentrations. 
However, it was noted that these drugs also have significant cytotoxicity at high 
concentrations. In fact, with the exception of SB 222200, the median toxic dose (TD50) 
of tested drugs was less than or equal to the 90% inhibitory dose (EC90) (Table 4.1). For 
this reason we used SB 222200 and TACR3 as models for further experiments. 
 
4.3.2 TACR1 and TACR3 are expressed in Huh 7.5 cells  
Given the activity of TACR1 and TACR3 antagonists in their inhibition of HCV 
infection, we next confirmed the presence of both receptors in Huh 7.5 cells. As shown 
in Figure 4.2C, both TACR1 (~53 kDa) and TACR3 (~55 kDa) appeared to be expressed 
in Huh 7.5 cells. However, the expression of both receptors appeared to be relatively 
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low. In addition, there appeared to be significant expression of both highly glycosylated, 
and truncated TACR1 and TACR3.  
 
 
 
Figure 4.1. Chemical structures of inhibitors used. A. TACR1 antagonists aprepitant 
and L 703606. B. TACR3 antagonists SB 222200 and osanetant. 
 
 
 
4.3.3 Blocking TACR3 reduces interferon stimulated gene expression in Huh 7.5 
cells  
PKC has been shown to be required for STAT phosphorylation and interferon-stimulated 
gene activation during IFN signaling(208). Since activating TACR potentially results in 
PKC activation, it is possible that TACR expression in Huh 7.5 cells is involved in 
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interferon signaling in this cell line. To confirm the receptor functionality in this cell 
line, we transfected Huh 7.5 cells with a plasmid expressing a reporter controlled by a 
promoter responsive to interferon stimulation. As shown in Figure 4.3, reporter activity 
was increased when cells were stimulated with IFN-β. As expected, IFN-stimulated 
reporter activity was reduced significantly upon treatment with 30 µM SB 222200 
(Figure 4.3). This indicates the potential functionality of TACR in Huh 7.5 cells. 
 
Compound EC50 (µM) EC90 (µM) TD50 (µM) TD90 (µM) 
Aprepitant 4.1 14.6 15.9 30.9 
L 703606 2.6 23.2 6.2 7 
SB 222200 7.3 24.6 >30 >30 
Osanetant 1.3 3.4 4.3 8.8 
 
Table 4.1. Dose response of TACR antagonists to HCV infection in Huh 7.5 cells. 
EC50, EC90, TD50 and TD90 values were calculated using OriginLab software. 
 
 
 
4.4 Discussion 
In this work we describe that the HCV inhibition of by TACR3 antagonists is not limited 
to SB 222200. We also show for the first time that TACR1 antagonists aprepitant and L 
703606 also significantly inhibit HCV infection. The TACR2 antagonist we tested, Men 
10376, did not show significant anti-HCV activity (data not shown). 
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Figure 4.2. TACR antagonists inhibit HCV infection. Huh 7.5 cells were treated with 
indicated inhibitors of TACR1 (A), or TACR3 (B) for 30 minutes prior to infection with 
Jc1 Gluc HCVcc for 12 hours. After incubation cells were washed and supernatants 
replaced with drug dilutions. HCV infection levels (shaded bars) were quantified based 
on secreted reporter Gluc in supernatants collected 48 hours later. Cytotoxicity (shaded 
circles) was quantified on these cells by using the CellTiter-Glo assay kit (Promega). 
Error bars represent the standard deviation of duplicate wells of two independent 
experiments. C. Western blots of Huh 7.5 cells showing expression of TACR1 or 
TACR3 as indicated. 
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Figure 4.3. TACR3 antagonist SB 222200 reduces interferon signaling. Huh 7.5 cells 
were transfected with plasmids encoding an interferon stimulated reporter (Fluc) gene 
and a control plasmid encoding another reporter (Rluc) gene for 8 hours. After 
transfection cells were treated with 30 µM SB 222200 or 4 U/ml IFN-α for 24 hours. 
IFN stimulation was quantified based on relative reporter levels (Fluc/Rluc) measured 
from cell lysates. Error bars represent the standard deviation of duplicate wells of two 
independent experiments.  
 
 
The high cytotoxicity exhibited by the tested drugs may be due to the fact that a 
hepatoma cell line was used, and TACR antagonists potentially have significant anti-
tumor effects (209, 210).  
 
The expression of both receptors in liver tissue has been implied based on an RT-PCR 
done by Pinto et al., but their protein expression in these cells has never been 
published(207). Consistent with the published RNA levels, protein expression level of 
both receptors appeared to be relatively weak (Figure 4.2C). In addition, there appeared 
to be a number of bands on the Western blot potentially due to the presence of 
glycosylated and truncated forms of the receptors. It should be noted that expression of 
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both truncated and glycosylated forms of TACR1 has been described in lymphoblastic 
leukemia cells by Munoz et al. (211). We also attempted to reduce the expression 
TACR3 in these cells in order to study its effect on HCV infection. However our 
attempts to knockdown the expression using both commercial siRNA pools (Figure 
4.4A) and shRNA expressed from a lentiviral expression vector (Figure 4.4B) were 
unsuccessful. 
 
 
 
Figure 4.4. Attempted knockdown of TACR3 in Huh 7.5 cells. A. 2.8 x 10
6
 Huh 7.5 
cells were electroporated with 500 pmoles siRNA pools against TACR3, with irrelevant, 
scrambled siRNA (Irr), or PBS (mock). Relative TACR3 RNA levels were quantified 48 
hours post electroporation by qRT-PCR. Error bars indicated the standard error obtained 
from duplicate wells. B. Huh 7.5 cells were transduced with pseudoparticles expressing 
shRNA against five different sequences of TACR3 mRNA (sh-TACR3-a-e). Three days 
post transduction, cellular RNA was isolated. Relative TACR3 mRNA levels were 
quantified by qRT-PCR. Error bars indicate the standard deviation obtained from 
duplicate wells. 
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The role of TACR in liver cells is currently unknown, but we were able to show to some 
extent that it may be functional in Huh 7.5 cells. This was done based on the known 
reliance of the interferon-pathway on PKC stimulation, and the fact that TACR has been 
involved in PKC activation in some cell lines (62, 208). By showing that TACR3 
antagonist SB 222200 reduces the expression of an interferon-stimulated reporter gene, 
we indicate that receptor stimulation may lead to PKC activation in these cells. 
Interferon stimulation effectively inhibits HCV infection, therefore reducing interferon 
stimulation, ceteris paribus, should increase HCV infection.  Therefore the role of the 
receptor in the HCV life cycle appears to not be limited to this pathway. In addition, the 
fact that there is a competing response to HCV replication (inhibition and potential 
enhancement) potentially explains why concentrations needed for HCV inhibition in 
these cells appear to be significantly greater than needed for receptor antagonism in 
other cell lines (212). 
 
Here we demonstrated that both TACR1 and TACR3 antagonists significantly inhibit 
HCV infection. This makes TACR1 antagonists more attractive as antiviral drug 
candidates, due to their ability to inhibit both HCV and HIV. However their path to 
becoming approved drugs remains limited by the lack of bioavailability and the high 
dosage requirement of the only currently approved TACR1 antagonist, aprepitant (89, 
213).  
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4.5 Materials and methods 
4.5.1 Chemicals, bacterial strains and cell lines  
Huh- 7.5 cells were obtained from Prof. Charles Rice (Rockefeller University).  
Cell lines were cultured in complete growth medium (Dulbecco’s Modified Eagle 
Medium (DMEM) containing 4500 mg/L glucose, 4.0 mM L- Glutamine, and 110 mg/L 
sodium pyruvate (Thermo Scientific HyClone) supplemented with 10 % fetal bovine 
serum (Atlanta Biologicals) and 1X non- essential amino acids (Thermo Scientific 
HyClone)). 
 
CellTiter- Glo Luminescent Cell Viability Assay Kit and Luciferase Assay System were 
purchased from Promega. Biolux Gaussia Luciferase Assay Kit was purchased from 
New England Biolabs. Dulbecco's Phosphate- Buffered Saline (DPBS) was purchased 
from Thermo Scientific HyClone. OptiMEM was purchased from Invitrogen. Luria- 
Bertani (LB) broth, Mirus TransIT LT1, Fugene-6 transfection reagent and ampicillin 
were obtained from Thermo Fisher Scientific. 0.25% trypsin- EDTA was obtained from 
VWR International. Aprepitant was obtained from Toronto Research Chemicals. L 
703606 was obtained from Sigma-Aldrich. SB 222200 was obtained from Tocris 
Bioscience. Osanetant was obtained from Axon MedChem. 
 
4.5.2 shRNA expressing pseudoparticle production 
shRNA-expressing pseudoparticles were generated based on a procedure previously 
described(90). Briefly, 293T cells were transfected for 6 hours with a 2:2:1 mass ratio of 
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HIV gag-pol, VSV-G, and shRNA expressing plasmid pLVTHM (19). The pLVTHM 
vector allows for expression of shRNA, and for identification of transduced cells based 
on GFP expression induced by a separate promoter. Cell supernatants containing VSV-G 
coated, shRNA expressing pp were collected 48 hours later, filtered and stored at -80 °C.  
 
4.5.3 Production and titering of infectious HCVcc 
JC1 HCVcc was generated from Huh 7.5 cells and titered as previously described(90). 
Briefly, 1 x 107 Huh 7.5 cells were suspended in 400 µl DPBS and electroporated with 5 
µg JC1-nsGauss HCV RNA using using an ECM 830 electroporator (Harvard 
Apparatus) at the following settings: 650 V, 99-μs pulse length, 5 pulses, 1.1-s interval. 
Cell supernatants were collected at 72, 96, 120, 144, 168 hours post electroporation, 
filtered and stored at -80 °C.  
 
4.5.4 HCV infection assay 
Huh 7.5 cells were seeded into wells of a 96 well plate at ~20% confluency. 6 hours 
later, cells were treated with drugs at indicated concentrations before infection with Jc1 
Gluc HCVcc at >0.1 MOI. 12-16 hours cells were washed and drug dilutions replaced. 
Cell supernatants were collected 48 hours post washing. HCV infection was quantified 
based on assayed Gluc levels in collected supernatants. Cell viability was quantified at 
this time using the CellTiter-Glo assay kit and by following the manufacturer’s 
instructions.   
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4.5.5 Interferon stimulation assay 
Huh 7.5 cells were seeded in a 24-well plate at 4 x 104 cells/well. The next, day cells 
were transfected with 0.5 µg/well of IFN-β reporter plasmid p125-Luc (214) and control 
plasmid pRL-TK at 10:1 mass ratios respectively, using Fugene-6 DNA transfection 
reagent. 24 hours later, cells were washed and treated with 30 µM SB 222200 or 4 U/ml 
IFN-α. Interferon signaling was determined based on intracellular Fluc levels measured 
24 hours later. Fluc generation was normalized to transfection efficiency in each well 
based on assayed Rluc values in that well. 
 
4.5.6 Western blotting 
Huh 7.5 cells were seeded into wells of a 6 well plate at 6 x 105 cells per well. Two days 
post seeding cells were lysed using Renilla lysis buffer (Promega). Cell lysates were 
denatured by combining with an equal volume of 2X SDS loading buffer and heating at 
95 °C for five minutes. Samples were separated using SDS-PAGE by running in a 12% 
acrylamide gel at 150 V for 60 minutes. After running samples were transferred to a 
PVDF membrane by running at 100 V for 80 minutes. Membranes were blocked in PBS 
containing 1% skim milk/0.1% Tween-20 (blocking buffer) for 30 minutes at room 
temperature. Next, membranes were incubated in blocking buffer containing 1000-fold 
diluted rabbit anti-TACR3 or 200-fold diluted goat anti-TACR1 primary antibodies 
(Santa Cruz Biotechnology), for 1 hour at room temperature. After incubation 
membranes were thoroughly washed with PBS before incubation with blocking buffer 
containing 1000-fold diluted HRP-conjugated goat anti-rabbit or donkey anti-goat 
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secondary antibodies as appropriate (Jackson ImmunoResearch) for 30 minutes at room 
temperature. Membranes were washed with PBS to remove blocking buffer, before 
development with West Femto Chemiluminescent HRP substrate (Pierce) and imaging.  
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5. CONCLUSIONS AND RECOMMENDATIONS 
 
 
In this work, we have developed an in vitro screening method that identified HCV 
inhibiting proteins. This screen identified a positively charged protein, B1, which 
significantly inhibited Jc1 HCV replication. We also identified a number of positively 
charged peptides during the screen, but were unable to verify their HCV inhibition. Our 
work indicates that the expression of positively charged proteins may be tightly 
regulated by expressing cells. This regulation reduces the overall inhibition seen by such 
proteins. In addition, we showed that a recombinant positively charged protein, +36GFP, 
significantly inhibited HCV infection. While this inhibition was not observed with B1, it 
marks the first incidence of defensin-like inhibition of HCV infection. We went on to 
show that recombinant B1 had significant cell-transduction capability. We showed that 
B1 was capable of delivery covalently-attached protein cargo into a wide range of 
mammalian cell lines. We also showed that B1 was capable of complexing and then 
transfecting mRNA into target cells as efficiently as commercially available transfection 
reagents. While we were unable to determine the mechanism of B1 mediated protein 
transduction, we found that B1 mediated RNA transfection was strongly dependent on 
clathrin-mediated endocytosis, and mannan receptor-dependent phagocytosis. Finally, 
we described the HCV inhibition of TACR1 and TACR3 antagonists. However, this is 
not intended to be the end of the line for any of these findings and it is hoped that these 
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findings will stimulate further interest in these fields. In fact, we believe that these 
results may be built upon in several ways.  
 
Firstly, the HCV inhibitor selection methodology outlined in section 2can potentially be 
enhanced and applied in different ways. Although the methodology was developed with 
the flexibility to identify inhibitors from any stage of the HCV life cycle, it can modified 
for more focused selection. This can be accomplished by using the fact that the 
developed cell line, n4mBID, uses a cell death based infection phenotype. Since only 
active HCV NS3-4A is required for initiation of the apoptotic cascade, n4mBID cells 
expressing only HCV NS3-4A are expected to be as apoptotic as HCV-infected n4mBID 
cells. As such, these cells can be used to screen for an HCV protease inhibitors. For 
example, in order to find small molecule inhibitors, seeded cells can be treated with 
inhibitor libraries, followed by transduction with pseudotyped lentivirals expressing 
HCV NS3-4A. In cells not treated with a protease inhibitor, significant cell death is 
expected at 3-4 days post transduction. Thus potential HCV protease inhibitors should be 
present in wells lacking significant cytotoxicity. Similarly, in order to find protein or 
peptide inhibitors of the HCV protease, a batch cells can first be transduced with a 
library of peptides/proteins using a lentiviral expression vector as done in section 2.  
After allowing time for gene expression, cells can then be transduced with lentivirals 
expressing HCV NS3-4A. After allowing 4-5 days for cell death, surviving cells can be 
rescued with the addition of a small molecule protease inhibitor such as VX950 (215). 
Selected lentivirals can be repackaged and used for subsequent rounds of selection, as 
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illustrated in Figure 2.1A. The advantages of this system, are that selected molecules 
will possess relatively little cytotoxicity, since they would be selected based on cell 
survival. Another advantage lies in the fact that the system allows for relatively easy 
validation of inhibition any of the genotypes of the HCV protease. This can be done 
simply by transducing cells treated with selected drugs, or expressing selected proteins 
with lentivirals expressing HCV NS3-4A of the desired genotype. However, 
disadvantages lie in the fact that drugs or proteins inhibiting lentiviral infection into 
these cells may be selected as false positives. In addition, drugs or proteins that inhibit 
caspase-mediated apoptosis may also be selected as false positives.  
 
Secondly, the HCV inhibition of positively charged proteins can be explored further. 
Though our data indicates potential for HCV inhibition by both intracellularly expressed 
and externally supplied positively charged proteins, in both cases their overall 
expression levels result in less inhibition than could be possible. We can attempt to 
improve the intracellular expressional stability of these proteins by including short, 
negatively charged, covalently linked expressing partners. This approach can be 
attempted since it has been shown that some defensins are expressed with negatively 
charged propieces hypothesized to aid their expression and folding(216).  As such, each 
expression partner should be designed such that the net charge on the construct 
approaches zero. In addition the cationic protein/peptide and its expression partner can 
be linked with a short repeat of a sequence such as: (glycine-glycine-serine) in order to 
promote proteolytic cleavage after expression, and release the ‘mature’ peptide/protein.  
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In addition, further work can be done to characterize the mechanism of inhibition of 
recombinant positively charged proteins.  
 
Thirdly, the cellular transduction efficiency of B1 can be improved upon. Unfortunately, 
the crystal structure of B1 is currently unknown, and so modifications based on surface 
charge or surface residues cannot readily be made. In addition, since a single ‘cell 
transduction’ motif within B1 cannot be identified, no straight-forward truncations can 
be made that would result in a smaller, more active protein. As such, in order to generate 
a more active version of B1, we can generate a library of B1 mutants, and select for 
mutants with increased cellular transduction activity. These mutants can be selected 
based on their ability to gain access to the cytosol, and then nucleus in a high percentage 
of cells. To accomplish this, the transduction of Cre-B1 fusion proteins can be quantified 
within target cells expressing a LoxP-recombination-dependent Gluc reporter gene. The 
advantage of using Cre is that the gene expression in each cell is dependent on whether 
transduction happened, or not. As such the results will not be biased towards mutants 
which might be able to transduce large amounts of protein into some cells, and smaller 
amounts into the remaining cells. To accomplish the screening, individual mutants 
should be used to transduce single wells of Cre reporter cells seeded into individual 
wells. In addition, both any selected mutants, and the original B1 should be subjected to 
further biochemical analyses in order to solve their crystal structure. This will potentially 
allow for improved understanding of residues positively affecting cell transduction. In 
addition, the cytosolic delivery of B1 can also potentially be improved by the addition of 
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a fusiogenic peptide to the C or N terminal of B1. This should be attempted since 
addition of such peptides have been demonstrated to improve the endosomal escape of 
other cell transducing proteins(126).  
 
We can also attempt to more conclusively determine the cellular transduction 
mechanism of B1. While we have shown that B1 mediated RNA transfection is 
dependent on endocytic and phagocytic processes (Figure 3.8), the mechanism of B1’s 
protein transduction remains elusive. In the absence of direct membrane penetration, 
many cellular proteins must be involved in B1-mediated cellular transduction. We will 
attempt to identify some of these proteins by determining B1 transduction efficiency in 
their absence. Any cellular process involves a combination of many proteins working 
together, and so some must necessarily be more critical than others. For example while 
clathrin mediated endocytosis involves at least 30 intracellular proteins, blocking some 
of these (for example clathrin) has a much more detrimental effect than blocking 
others(217). However, we have shown that B1 mediated protein transduction may not be 
inhibited by blocking known endocytic pathways. This means that blocking or 
monitoring the activity of common markers of endocytic processes, such as the 
regulation of Rho and Rac GTAases, cannot be expected to yield very meaningful data. 
Since B1 appears to use an alternate or non-canonical pathway to enter cells, a broader 
approach to identifying these proteins must be taken (218, 219). In order to efficiently 
identify these genes, we will screen for activity from a library of candidates. Such an 
approach has been used to identify viral entry factors by using siRNA libraries to knock 
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down cellular proteins (220, 221). We can accomplish this by using an siRNA library 
designed to knock down genes associated with membrane trafficking, and then 
quantifying B1 protein transduction in their absence. Genes appearing as hits can be 
further characterized by using shRNA targeting identified genes to generate stable cell 
populations with these genes knocked out. At the same time, we can generate cell lines 
that over-express these genes, and determine the relative transduction efficiency in these 
cells, compared with naïve cells. If the targeted genes are solely responsible, or represent 
a limiting step in the process, then overexpressing them should increase transduction 
efficiency. We can also confirm the role of identified genes by attempting transduction 
in the presence of drugs that block their action, if such drugs are available. Finally we 
can compare the role of the identified genes in B1 transduction with the transduction of 
other CPPs. Using our knock-out cell lines and naïve cell lines, we will compare the 
transduction efficiency of Cre-Tat, Cre-R10, and Cre-+36GFP with Cre-B1. These 
experiments should provide some definitive comparisons of the mechanisms used by 
these CPPs. 
 
Finally, we can find an improved TACR1 or TACR3 antagonist that may have a more 
favorable pharmacological profile in vivo. This can be done by testing the anti-HCV 
activity TACR1/3 antagonists with more limited ability to cross the blood-brain barrier, 
and with increased oral bioavailability. Though such drugs would be less attractive for 
the more traditional antiemetic and analgesic indications of TACR antagonists, they 
would undoubtedly present less unintended side effects when used in vivo.  
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